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T cells mediate adaptive immune responses via activation of other 
immune cells and regulation of tissue cells to eliminate bacterial, fungal and 
viral pathogens and maintain homeostasis. Based on cytokine production 
patterns, T helper cells were classically subdivided into Th1, Th2 and T 
regulatory cells. Recently, new subsets of T helper cells, including Th9, Th17 
and Th22 cells have been described. One of the cytokines produced by Th17 and 
Th22 cells is interleukin-22. Because of preferential expression of IL-22R1 on 
cells of epithelial origin, IL-22 is a unique cytokine produced by immune cells, 
which acts only on tissue cells. Among all T helper cells subsets, IL-22-
producing T cells are characterized to a lesser extent as compared to other cells. 
In this PhD thesis, I have studied human IL-22-producing T cells in depth and 
further characterized them. 
The data demonstrated in these studies is novel in terms of three aspects. 
First of all, for the first time miRNA expression analysis in human IL-22-
producing T cells has been performed and new miRNA-323-3p has been 
reported as a potential negative regulator of IL-22 production from T cells. 
Secondly, next generation sequencing of human IL-22-producing T cells sorted 
with in-house generated IL-22 secretion assay was performed and full profile of 
IL-22-producing T cells including potential transcription factors was provided. 
Finally, a novel double cytokine secretion assay that allows sorting of viable 
Th22 cells that do not co-produce IL-17A was generated.  
Better understanding and characterization of human Th22 cells may 
provide novel therapeutic options in the treatment of diseases like psoriasis, 
atopic dermatitis, rheumatoid arthritis, where a pro-inflammatory role of IL-22 







T-Zellen vermitteln die adaptive Immunantwort über die Aktivierung 
weiterer Immunzellen und der Regulierung von Gewebezellen um bakterielle, 
pilzartige und virale Pathogene zu eliminieren und die Homöostase 
aufrechtzuerhalten. Basierend auf dem Zytokinproduktionsmuster, werden T-
Helferzellen üblicherweise in Th1, Th2 und T-regulatorische Zellen unterteilt. 
Kürzlich wurden neue Untergruppen von T-Helferzellen wie Th9, Th17 und 
Th22 – Zellen definiert. Th17 und Th22-Zellen produzieren vorwiegend 
Interleukin-22. Aufgrund der bevorzugten Expression von IL-22R1 in 
Epithelzellen ist IL-22 ein Zytokin, welches speziell nur auf Gewebezellen 
wirkt. Unter den T-Zelluntergruppen sind IL-22-produzierende T-Zellen 
weniger gut charakterisiert als andere. In dieser PhD Thesis habe ich humane 
IL-22-produzierende Zellen untersucht und das Wissen über diese erweitert.  
In dieser Studie werden Daten gezeigt, welche bezüglich dreier Aspekte 
neuartig sind. Zunächst, wurde erstmalig eine miRNA Expressionsanalyse in 
humanen IL-22-produzierenden T-Zellen durchgeführt und miRNA-323-3p 
wurde als ein potentieller negativ-Regulator für die Produktion von IL-22 in T-
Zellen beobachtet. Zweitens wurde ein next generation sequencing von humanen 
IL-22-produzierenden T-Zellen mit einem selbst generierten IL-22 
Sekretionsassay durchgeführt. Das gesamte Profil von IL-22-produzierenden T-
Zellen, inklusive potentielle Transkriptionsfaktoren, wurde dabei ermittelt. 
Drittens wurde ein neuartiger doppel-Zytokin Sekretionsassay entwickelt, 
welcher das Sortieren von viablen Th22-Zellen ermöglicht, die kein IL-17A 
koproduzieren.  
Das bessere Verständnis und die Charakterisierung von humanen Th22-
Zellen könnte dazu beitragen, neue Therapiemöglichkeiten in der Behandlung 
von Krankheiten zu finden, in welchen IL-22 eine proinflammatorische Rolle 




4 Abbreviations  
 
3` UTRs 3` untranslated regions 
AD atopic dermatitis 
Ag antigen 
AGO  Argonaute protein 
AhR aryl hydrocarbon receptor 
APC antigen presenting cell 
Bcl-2 B-cell lymphoma 2 
C domain  constant domain 
CD disease Crohn`s disease 
CDRs  complementarity-determining domains 
CNS central nervous system 
c-SMAC  central – SMAC 
CTL cytotoxic T lymphocytes 
CXCL CXC chemokines ligand 
DC dendritic cell 
dsRNA double stranded RNA 
EAE experimental autoimmune encephalomyelitis 
ER endoplasmic reticulum 
GM-CSF  granulocyte-monocyte colony stimulating factor 
HIV human immunodeficiency virus 
HSV-1 herpes simplex virus type 1 
IBD infalmmatory bowel disease 
ICAM intercellular adhesion molecule 
IELs intraepithelial leukocytes 
IFN interferon 
Ig  immunoglobulin  
IL interleukin 
IL-22BP IL-22 binding protein 
IL-22R IL-22 receptor 
ILCs innate lympoid cells 
IL-TIF  IL-10-related-T cell-derived inducible factor 
IRF interferon regulatory transcription factor 
ITAMs  immune-receptor tyrosine-based activation motifs 
LFA lymphocyte function-associated antigen 




LRRs leucine-rich repeats 
MAPK mitogen-activated protein kinase 
MD2 myeloid differentiation factor 2 
MHC major histocompatibility compex 
miRISC miRNA-induced silencing complex 
miRNA microRNA 
MMP matrix metalloproteinase 
mTOR mammalian target of rapamycin kinase 
MyD88 Myeloid differentiation factor 88 
ncRNA non-coding RNA 
NF-κB nuclear factor kappa beta 
NK cell natural killer cell 
NKT cell  natural killer T cell 
NLRs NOD-like receptors 
OVA  ovalbumin 
PAMPs pathogen-associated molecular patterns 
PBMC`s peripheral blood mononuclear cells 
PI3K phosphoinositide 3-kinase 
poly(I:C) polyinosinic-polycytidylic acid 
PPRs pathogen recognition receptors 
pre-miRNA precursor microRNA 
pri-miRNA primary microRNA 
p-SMAC  peripheral – SMAC 
PTs palatine tonsils 
RA  rheumathoid arthritis 
Rag recombination-activating gene 
REG regenerating islet-derived protein 
RLRs RIG-like receptors 
RSV respiratory syncytial virus 
SMAC  supramolecular activation complex 
SOCS1 suppressor of cytokine signalling 1 
ssRNA  single stranded RNA 
STAT  signal-transducing activators of transcription  
T reg  T regulatory cel 
Tc cell cytotoxic T cell 
TCR  T cell receptor  




TMCs  Tonsil mononuclear cells  
Th cell  T helper cell 
TIR  Toll/IL-1 receptor 
TIRAP TIR domain-containing adaptor protein 
TLRs Toll-like receptors 
TRAF tumor necrosis factor receptor-associated factor 
TRAM  TRIF-related adaptor molecule 
TRIF TIR-domain-containing adaptor-inducing IFN-γ factor 
UC  ulcerative colitis 



























5 General introduction 
5.1 Historical background 
The immune system developed during evolution to ensure that multi-
cellular organisms are protected from pathogens. To match the diversity of 
pathogens invading our body, the immune system requires a broad range of 
recognition and elimination mechanisms. The above mentioned protection is 
provided by sophisticated and powerful network of organs, tissues, cells, 
molecules and pathways. Immunology as a scientific discipline, grew out of the 
observation that individuals, who had recovered from infectious diseases were 
protected from them when encountered for the second time. The origin of 
immunology has dated back to the late 18th century when the English physician 
Edward Jenner observed that milkmaids that contracted cowpox disease were 
immune to severe smallpox. Based on this observation, in the procedure called 
vaccination, he inoculated people with fluid from the cowpox postule and by 
which protected them from smallpox. Later, Robert Koch proved that infectious 
diseases are caused by microorganisms. Those discoveries of Koch and Jenner; 
opened new possibilities of vaccinations against other diseases. In the years 
1881-1886, Louis Pasteur developed protection strategies against cholera, rabies 
and anthrax. The need to search for and understand the mechanisms underlying 
protection against infectious diseases led to the development of immunology as 
a science.  
Immune system protects the host from the invasion of pathogens. The 
main success in the field of immunology is that a lot of infectious diseases have 
now been eradicated, the others are fully controlled, organ transplantation is 
possible, and immune-related drugs used to treat life-threatening disorders. 
Nevertheless, a range of disorders can still result from defective immune 




allergies), autoimmune diseases, immune deficiencies and during the 
development of cancers [1-3].  
5.2 Principles of innate and adaptive immunity  
Four main tasks must be fulfilled by the immune system to effectively 
protect against a disease. First of all, the presence of infection must be detected 
in the process of immunological recognition. Later, infection must be contained 
and if possible completely eliminated with the help of the effector functions of 
immune cells. In parallel, the immune system has to self-regulate and keep its 
own response under control. Failure of the immune regulatory function may 
contribute to the development of inappropriate immune reactions, like those 
observed in many of the allergies or the autoimmune diseases. Lastly, 
individuals exposed at least once to infections agents should develop 
immunological memory, which will ensure stronger and faster protective 
immunity when facing subsequent exposure to the same pathogen. To be able to 
fulfill completely those tasks there are two interconnected types of immunity: 
innate and adaptive.  
Mechanisms of innate immunity are encoded in the germline and 
developed earlier during evolution. The recognition strategies used in innate 
immunity are fast reacting, but not very precise and specific. This first line of 
defense is focused on prevention of infection and quick elimination of common 
threats via physical and chemical barriers, pathogen recognition receptors, 
phagocytes, and broad range of serum proteins. 
On the other hand, adaptive immune system is specific for subtle 
molecular differences of each individual pathogen. The system relies on B and T 
lymphocytes, which via randomly generated receptors ensure antigen-specific 
responses. The fact that only few cells possess the specific receptor and those 
cells undergo clonal selection and proliferation upon Ag recognition. In 




significant feature of adaptive immune system is ability to remember prior 
exposure and generate immunological memory to respond faster and with 
greater efficiency upon repeated exposure to the same pathogen.  
The accurate development of adaptive response is dependent on innate 
immunity that is why both systems do not exist separately, they are dependent 
upon one another and cooperate for maximal effectiveness in protection of the 
host [1-3]. 
5.3 The innate immune system 
The innate immune system consists of physical and chemical barriers as 
well as cellular responses against infection. The epithelial cells of skin and 
respiratory, gastrointestinal and urinary mucosal tissues are the anatomical 
barriers, which prevent pathogens enter the body. Formation of anatomical 
barrier is possible due to the fact that epithelial cells are connected with each 
other via tight junction molecules, and form a seal against the external 
environment. Besides providing a passive barrier function, the epithelial lining 
of mucosa also actively contribute to immunity by the production of 
antimicrobial peptides, reactive oxygen and nitrogen species, cytokines, 
chemokines and mucus [4, 5]. 
Despite the protection by epithelial cells, many pathogens developed 
strategies to by-pass these layers. The next line of defence is composed of 
phagocytes, namely macrophages, neutrophils and dendritic cells. Phagocytes as 
well as epithelial cells, via pathogen-recognition receptors (PRRs), directly 
recognize pathogen-associated molecular patterns (PAMPs) present on many 
microorganisms. PRRs as one of the most important invariant receptors of innate 
immunity detect and trigger effective defence against pathogens. They recognize 
microbial products that are very crucial for the microbes’ survival, so ensuring 
microbes cannot adapt and evade recognition by the host. Some of PRRs, like  




recognition trigger phagocytosis. The others, particularly Toll-like receptors 
(TLRs), NOD-like receptors (NLRs), RIG-like receptors (RLRs) trigger 
transcription pathways of genes encoding antimicrobial peptides, interferons, 
cells recruiting and activating chemokines and cytokines, enzymes, all with 
important functions in protective immunity. Broad spectrum PRRs, located 
inside as well on the cell surface, ensures that the cell is able to recognize 
PAMPs from intracellular and extracellular pathogens [1-3]. 
The innate immune system not only recognizes conserved microbial 
structures but also DAMPs (damage-associated molecular patterns), the 
endogenous products releases from dying or damaged cells. 
Until now 5 different classes of PRRs have been identified: Toll-like 
receptors, retinoic-acid-inducible gene-I-like receptors, nucleotide-binding 
domain and leucine-rich repeat containing gene family, C-type lectin receptors 
and cytosolic DNA receptors [6, 7].  
5.3.1 Toll-like receptors  
Toll-like receptors, the prototype PRRs, were characterized as a unique 
factor responsible for Drosophila melenogaster development and immunity  
[8, 9]. The spectrum of PAMPs recognized by TLRs is very broad, including 
nucleid acids, proteins, lipoproteins and lipids from microbes such as parasites, 
fungi, viruses and bacteria [10]. This membrane bound family of PRR sense 
PAMPs on the cell surface (TLR1, TLR2, TLR4, TLR6) as well as in the 
endosomes (TLR3, TLR7, TLR8, TLR9) and share a common structural element 
in the extracellular region called leucine-rich repeats (LRRs) [11]. The 
subdivision of TLRs based on their localization is related with the category of 
PAMPs they recognize. The group recognizing microbial membrane 
components is localized on the host cells surface and the group that recognize 
microbial nucleid acids is exclusively expressed in the intracellular vesicles 




endosomes. So far, 10 functional TLRs were identified in humans (TLR1-
TLR10) and 12 in mice (TLR-1-TLR13) with TLR10 being not functional and 
each with a distinct repertoire of specificity against PAMPs (described in  
Table 1) [12]. In Table 1, all known human TLRs and their corresponding 
ligands are shown.  
 
Table 1. Toll-like receptors and their microbial ligands  
TLRs Ligand Microbes Localization 

























Cell surface / 
Endosomal 




Mycobacteria and Gram-positive bacteria 
Yeast and other fungi 
Cell surface 
TLR7 ssRNA Viruses Endosomal 
TLR8 ssRNA Viruses Endosomal 
TLR9 
CpG unmethylated dinucleotides 
Dinucleotides 





Malaria parasite heme byproduct 
Endosomal 










5.3.1.1 Cell surface TLRs 
TLR4, the first described TLR, is responsible for binding to 
lipopolisaccharide (LPS), the main component of the cell wall from gram-
negative bacteria [13]. The LPS-binding component is formed by TLR4 and 
MD2 (myeloid differentiation factor 2), The TLR4-MD2-LPS complex initiates 
the signal transduction. Recently, it has been show that TLR4 is not only 
involved in recognition of TLR4 but can recognize pneumolysin from 
Streptococcus pneumoniae, envelope proteins of the mouse mammary tumor and 
the fusion proteins of respiratory syncytial virus (RSV) [10]. Another member of 
TLRs family expressed on the surface is TLR2 that is responsible for 
recognition of lipopeptides from bacteria, peptidoglycan and lipoteichoic acid 
from Gram-positive bacteria, lipoarabinomannan from mycobacteria, zymosan 
from fungi, tGPI-mucin from Trypanosoma cruzi, hemagglutinin protein from 
the measles virus [10]. The unique feature of TLR2 is that it forms heterodimers, 
either with TLR1 to recognize triacylated lipopeptides or with TLR6 to 
recognize diacetylated lipoproteins [14, 15].  TLR5 recognize bacterial flagella 
[10]. Cells that express high levels of TLR5 are lamina propria dendritic cells 
from the small intestine (CD11c+CD11b+), which are involved in the promotion 
of Th17 and Th1 cell development and induction of IgA-producing plasma cells 
[16]. TLR10, because of its sequence similarity to TLR1, might form 
heterodimers with TLR2, but so far the role of TLR10 is not known [12].  
5.3.1.2 Intracellular TLRs 
Discovered in 2001, TLR3 was the first TLR that was shown to be 




acid (poli (I:C)), a synthetic analog of double-stranded RNA, which mimics a 
viral infection, was used to identify TLR3 ligands. Nowadays, it is well 
established that TLR3 mediates recognition not only of poli (I:C), but recognizes 
the genomic RNA of reoviruses, single stranded RNA (ssRNA) viruses like 
RSV virus, encephalomyocarditis virus, West Nile virus, which produce dsRNA 
during replication in host cells [10, 18]. The essential role of TLR3 in the 
activation of type I interferon (IFN). The mammalian types are designated  
IFN-α (alpha), IFN-β (beta), IFN-κ (kappa), IFN-δ (delta), IFN-ε (epsilon),  
IFN-τ (tau), IFN-ω (omega), and IFN-ζ (zeta, also known as limitin) [19], as 
well NF-kB signalling pathways and preventing virus infection is clearly evident 
in TLR3 deficiency in humans, who are susceptible to herpes simplex virus  
type 1 (HSV-1) infection [20]. In the mouse models, it was shown that TLR3 
deficient mice are highly susceptible to the infection with murine 
cytomegalovirus [21]. 
TLR7 was identified in the experiments in, which antiviral and antitumor 
drugs (imiquimod, resiquimod, loxirinine) were recognized by this TLR7. 
Additionally, TLR7 recognizes ssRNA of human immunodeficiency virus 
(HIV), influenza A virus and vesicular stomatitis virus [10, 22]. Plasmacytoid 
dendritic cells (pDC), which produce type I IFN`s after virus infections, express 
high levels of TLR7. Similarly to TLR7, TLR8 recognizes viral ssRNA as well. 
The last of the intracellular TLR`s characterized so far, TLR9 recognizes 
unmethylated-CpG DNA (2`-deoxyribo (cydidine-phosphate-guanosine)) 
motifs, that are rare in mammalian cells but are present in bacteria and viruses. 
Direct activation of dendritic cells, macrophages and B cells is possible by 
synthetic CpG oligodeoxynucleotides, which serves as TLR9 ligands. It was 
shown recently that stimulation of B cells via TLR9 induce IL-10 production 




5.3.1.3 Signal transduction pathways and generated 
response 
Toll-like receptors` cytoplasmic domain contains the so-called TIR 
domain (Toll/IL-1 receptor) that serves as the binding site for TIR domains of 
adaptors involved in the downstream signalling pathway. There are two main 
adaptors: MyD88 (Myeloid differentiation factor 88) and TRIF (TIR-domain-
containing adaptor-inducing IFN-β factor) and two main sorting adaptors: 
TRAM, that recruits TRIF to endosomal TLR4 and TLR3, and TIRAP that 
recruits MyD88 to TLR2 heterodimers and TLR4. MyD88 adaptor molecule 
binds to most of TLRs except TLR3 to which the TRIF adaptor protein binds. In 
the MyD88-dependent signalling pathway MyD88 binds to TIRM domains of 
the plasma membrane TLR2/1, TLR4, TLR5 and induce NF-kB and MAPK 
pathways. Additionally, the activation of the NF-kB and MAPK in the MyD88 
dependent pathways, TLR7, 8 and 9 also activate interferon regulatory factors 
(IRFs), that are fundamental in the transcription of type I interferon genes.  
Alternatively, in the TRIF-dependent signalling, TLR3 and endosomal 
TLR4 recruits TRIF adaptors. Interestingly, when TRIF recruits RIP1 protein 
kinase it activates the very same steps as in MyD88 dependent pathway, when it 
activates PI3K, it induces MAPK pathway and finally when it activates TRAF3 
it activates IRF3 and IRF7 [10].  
5.3.2 Direct activation of TLRs in CD4+ T cells 
Studies characterizing TLRs function have been mainly focus on the cells 
of innate immunity, but there is evidence that TLRs are important for T cells 
function and adaptive immunity as well. At the mRNA level, expression of all 
TLRs was confirmed for CD4+ T cells [24-26]. Expression of TLR2, 3, 4, 5, 9 
has been also detected by flow cytometry [27-29]. Since TLRs expression in T 




depends on their functional and activation status [30-34]. Expression of selected 
TLRs and its effect on T cells is shown in Table 2. 
The most of the knowledge about the role of TLRs in T helper cells come 
from studies about TLR2. Toll-like receptor 2 signalling in naive CD4+T cells 
promotes IFN-γ production and differentiation into Th1 cells. Furthermore, 
TLR2 is the only TLR, which could induce proliferation and IFN-γ production 
from already differentiated Th1 cells [28]. Additionally, TLR2 influence Th17 
cells development and function since Th17 cells differentiation was found to be 
promoted by TLR2 [35, 36]. Moreover, restimulation of activated T cells with 
TLR2L induced production of IL-17 [37]. In a Th17 dependent EAE 
(experimental autoimmune encephalomyelitis) model, T cells lacking TLR2 
were unable to induce the disease [36]. In summary, TLR2 activation is involved 
in the regulation of Th1 and Th17 cells functions.  
On the contrary, proliferation and survival of the naive T cells activated 
via TLR4 is observed, rather than the direct promotion of T helper cells 
differentiation [38]. In vivo, the role of TLR4 in T cells highly depends on the 
site of action. In the central nervous system (CNS), loss of TLR4 in CD4+T 
cells, protected against EAE via decreased IFN-γ and IL-17 production at the 
site of infection but not in the periphery [38]. On the contrary, in gut TLR4 
deletion led to enhance IFN-γ production and severe colitis [39]. Finally, 
activation of TLR4 on T cells enhances the ability of CD4+T cells to bind 
fibronectin and migrate [40].  
Growing number of evidence suggest that not only plasma membrane 
bound TLRs are functional in CD4+T cells but also activation of human CD4+T 
cells via endosomal TLR9 enhanced expression of activation markers and entry 
into the cell cycle [41]. Unlike for TLR2, 4 and 9, most studies about TLR3 
function in T cells were performed in humans. TLR3 is expressed on human 
CD4+ and CD8+ T cells [41] and its stimulation induces the transcription factor 




CCL3, CCL4, CCL5 expression [42]. Interestingly, stimulation of TLR3 with 
poli (I:C) in the presence of anti-CD3 and anti-CD28 antibodies, induced NF-kB 
dependent synthesis of IL-17A and IL-21. Stimulated cells do not express 
classical helper T cell transcription factors like T-bet, Gata-3 nor RORγt [44].  
Several groups have shown that in the absence of CD28 involvement, 
TLRs may provide co-stimulatory signals for T cells [27, 28]. Importantly, in 
the absence of TCR stimulation, TLRs do not induce functional responses in 
naive T cells, preventing non-specific T cell activation by TLRs alone [45]. 
 
Table 2. Effect of selected TLRs on activation of T cells 
TLRs 
Expression in T cell subsets 
Effect on T cells 
Naïve Activated/Memory iTreg 
TLR1 ± ++ + 
 Increased proliferation and survival 
 Abrogate the suppressive function of Tregs 
TLR2 ± ++ + 
 Increased cell proliferation and survival 
 Promote cytotoxic activity of CTL 
 Generate efficient memory T cells 
 Augment Treg cell proliferation with temporal 
loss of suppression 
 Induction of cytokines production  
(IFN-γ, IL-17A, IL-10, IL-13, CCL5, CXCL10) 
TLR3 + ++ - 
 Promotion of activated CD4+T cells survival 
 Induction of cytokines  
(CXCL10, CCL3, CCL4, CCL5, IL-17A, IL-21) 
TLR4 ± ++ + 
 Induce Treg cell activation 
 Enhance the suppressive function of Tregs 
TLR6 + + +  Block the suppressive function of Tregs 
TLR9 + ++ - 
 Promote survival of activated CD4+T cells 
 Inhibit Treg cell suppression 
 
 
Expression levels: (-) not detectable, (±) weak or low expression, (+) normal, (++) enhanced  




T and B lymphocytes are the essential cells of the adaptive immune 
system. In contrast to cells of the innate immunity, mature B and T lymphocytes 
differ from each other in terms of specificity – they express a highly specific and 
diverse repertoire of antigen recognizing receptors on the cell surface. The 
adaptive branch of the immune system may be subdivided in to humoral and 
cellular-mediated immunity, which differ in the mechanisms they use and the 
type of pathogens they respond to. Antibodies, the main molecules of humoral 
adaptive immune system, are involved in microbial antigen recognition, and 
elimination in blood and mucosa tissues. In general, this type of immunity 
targets extracellular microbes and their products by direct binding with produced 
antibodies. On the other hand, cellular immunity involves T helper cells for the 
induction of immunity against intracellular microbes that are normally not 
accessible for antibodies. This section focuses on the T cell mediated immune 
responses, with a special emphasis on CD4+ T helper cells.  
5.4.1 T lymphocytes 
5.4.1.1 T cell receptor (TCR) 
T cells recognize antigens that are presented via major histocompatibility 
molecules (MHC) by antigen presenting cells (APC). As a result, T cells do not 
respond to soluble antigens but only to cell-surface associated antigens. The 
TCR was discovered in the early 1980s, using monoclonal antibodies 
recognizing a single cloned T-cell line [46]. There are two types of TCRs, both 
heterodimers, both consisting of transmembrane polypeptide chains. Most of the 
circulating T cells express αβ while the minority expresses γδ chains.  Each 
chain of the TCR consists of a short cytoplasmatic region, hydrophobic 
transmembrane region, N-terminal variable domain (V) and constant domain 
(C). In variable domains of the two chains three hyper-variable, so-called 
complementarity-determining regions (CDRs), are present. CDRs are the part of 




cytoplasmic regions of TCRs are too short to transduce signals into the cell and 
trigger activation. Signaling via TCR depends on a complex of CD3 molecules: 
δε (delta/epsilon), γε (gamma/delta), ζζ (zeta/zeta) dimers. Cytoplasmic parts of 
all CD3 molecules contain immune-receptor tyrosine-based activation motifs 
(ITAMs) [48]. During the antigen recognition by T cells, ITAMs become 
phosphorylated and initiate signal transduction. The contribution of the CD3 
complex in the signal transduction by TCR is not sufficient to activate the cells. 
To facilitate signaling and T cell activation, CD4 and CD8, two TCR co-
stimulatory molecules, recognizing the MHC-peptide complex, are necessary. 
CD8+ T cells recognize peptides presented by antigen presenting cell in the 
context of MHC class I and function primarily as cytotoxic cells, while CD4+ T 
cells recognize MHC class II molecules and function mainly as helper cells [49, 
50]. Figure 1 shows the structure of the TCR receptor complex.  
 
 
Figure 1. T cell receptor complex on CD4+ T cells. 
 
 




Microorganisms rapidly evolve and to protect the host, the immune 
system must be diverse and flexible in their recognition. B and T cells express 
highly diverse antigen receptors. The diversity of receptors are generated during 
the development of B and T cells. In this section, the principles of TCR gene 
rearrangement are described.  
 Each TCR locus consists of V and J gene segments, as well as C region 
located 3` of J segment. There are 2 constant region genes in each of human 
TCR β and TCR γ and only one each for TCR α and TCR δ.  For all TCRs, the 
constant region is composed of 4 exons encoding: the cytoplasmic tail, the 
transmembrane segment, the hinge region, and the extracellular region. In 
addition TCR β and δ loci have D segments. During the T cell development in 
the process of somatic recombination a functional V exon region of the α chain 
is form when the Vα segment rearranges to the Jα gene segment. Transcription 
and splicing of the VJα exon to Cα generates the mRNA that is translated to 
TCRs chain protein. In the case of the β chain, the rearrangement of Vβ, Dβ, Jβ 
segments generates a functional VDJβ V-region exon that is transcribed and 
spliced to join Cβ. Finally, mRNA is translated to T-cell receptor β chain, and 
soon after synthesis the α and β chains form a heterodimer [51, 52]. The 
combinatorial and junctional diversity during the process of gene rearrangement 
shape the diversity of T cell receptors. Lastly, T cell receptors after completing 
rearrangement do not diversify further their variable regions in the process of 
somatic hypermutation as it happens in case of antibodies [2].  
5.4.2 Antigen presentation and T cell activation  
In contrast to B cells, T cells respond only to short amino acid sequences that are 
formed when protein is unfolded, processed and cut into peptides, which 
displayed in the context of major histocompatibility molecules [53, 54]. There 
are 2 types of MHC molecules, which differ in structure, the nature of presented 




II molecules in cell types triggers different effector functions by T cells. MHC I 
is expressed on almost all nucleated cells and presents peptides derived from 
intracellular pathogens.  MHC I present peptides to CD8 cytotoxic T cells, 
which in turn kills the infected cells. On the contrary, CD4 T cells recognize 
MHC II-peptide complexes and activate other cells of immune system. MHC II 
molecules are expressed exclusively on professional APC`s: DC`s, macrophages 
and B cells. If antigen is presented by B cells to CD4+ T cells, they stimulate  
B cells to produce antibodies. When foreign antigen is presented by 
macrophages, T cells activate them to destroy the pathogens inside the cell  
[55-57]. From all professional APC`s, DC`s are considered as the most effective 
in the antigen presentation to naive T cells [58, 59]. If the pathogen enters body 
directly into the bloodstream it is taken up by APCs located in spleen. Pathogens 
infecting tissues directly, are recognized by immature tissue resident DC`s. 
During the antigen (Ag) recognition DCs are activated by PAMP, DAMPs or via 
cytokines produced during the inflammatory response. Next, activated DCs 
migrate to the nearest lymph nodes, where they present antigen to antigen 
specific naive T cells, activate them and trigger differentiation into effector T 
cells [60, 61]. 
T cell development occurs in the thymus, where T cells with diverse TCR 
specificities, tolerant to self and restricted to self-MHC molecules are generated.  
As soon as T cells undergo positive and negative selection and their lineage is 
committed, they leave the thymus as a mature, naïve T cell enter the circulation 
[62-65]. Later, they re-circulate between the blood and peripheral lymphoid 
organs, searching for specific peptides presented via MHC molecules on APC. 
In lymph node, naive T cells binds temporally to every APC via LFA-1, CD2 
and ICAM-1, ICAM-2, CD58 interaction between T cells and APCs. At the 
time, when naive T cell recognizes specific peptide loaded MHC molecules, the 
initial binding of adhesion molecules increases its affinity and the connection 




called immunological synapse or supramolecular activation complex (SMAC). 
During formation of immunological synapse, the contact surface between APC 
and T cell is organized into 2 areas: the central supramolecular activation 
complex (c-SMAC), where MHC-TCR, co-stimulatory and co-receptor 
molecules, responsible for T cell activation are located, and the peripheral-
SMAC (p-SMAC) where adhesion molecules and their ligands, cytoskeletal 
protein connecting integrins to actin are found. Clustering of T-cell receptors in 
the c-SMAC triggers re-orientation of cytoskeleton and polarization of T cell 
towards the APC [66-68]. Signal provided only by the recognition of peptide 
bound to the MHC molecule by the TCR on T cells is not enough to trigger T 
cell activation and differentiation [69]. Two other signals are indispensable: 
interaction between costimulatory molecules that provide the 2
nd
 signal, and 
cytokines produced by APCs that directly drive T cells differentiation into 
specific effector subsets, serves as the 3
rd
 signal. CD28 is the best characterized 
costimulatory receptor of T cells that binds to CD80 or CD86 costimulatory 
ligands on dendritic cells to administer signal number 2 [70, 71]. CD28 is 
expressed by all naïve and activated human CD4+T cells The main role of CD28 
– CD80/CD86 interaction is to enhance TCR induced proliferation and survival 
by inducing expression of IL-2 and α chain of IL-2 receptor by T cells [72]. T 
cells activated in this way divide rapidly to generate a sufficient number of 
antigen specific T cells to eliminate antigens in process called clonal expansion. 
The 3
rd
 signal, is provided by polarizing cytokines, which determines the 
functional fate of activated T cells. CD4+T cells differentiate into effector cells 
that are characterized by: subset inducing polarizing cytokines, lineage specific 
transcription factors, and a range of cytokine produced to convey effector 
function [73]. The main classes of effector T cells are: Th1, Th2, Th9, Th17 and 
Th22 cells [74, 75]. Figure 2 shows the immunological synapse formation 





Figure 2. The immunological synapse formation and 3 signals activating  
















5.4.3 Effector T helper cell subsets 
5.4.3.1 Th1 cells  
IFN-γ and IL-12 are the 3rd signal cytokines that when provided to naïve T 
cells drive their differentiation into Th1 cells [76]. Those cytokines are produced 
in response to microbes by activated DC`s, macrophages and NK cells. Two 
signal-transducing activators of transcription molecules (STATs), STAT 1 and 
STAT 4 contribute to Th1 cell development and are activated by IFN-γ and  
IL-12, respectively. Activated STAT 1 induces expression of T-bet transcription 
factor, the master regulator of Th1 differentiation [77]. The main function of  
T-bet is activation of gene transcription of IFN-γ and IL-12 receptors and IFN-γ. 
Promotion of the expansion and differentiation of Th1 cells is provided by  
IL-12 activated - STAT4 that enhances further IFN-γ production. In the process 
of cross-regulation between other T helper subsets, differentiation of naïve T 
cells to Th2 and Th17 cells is inhibited by IFN-γ. The main function of Th1 cells 
is the protection against intracellular pathogens. IFN-γ produced by Th1 cells, 
activates macrophages to neutralize phagocytosed pathogens [78]. Additionally, 
IFN-γ promotes antibody class switching mostly to IgG isotypes. These 
antibodies help complement activation and phagocytoses of opsonized microbes 
[79]. Recent work from our group showed the relationship between Th1 
mediated immune responses and epithelial tissues. Upon IFN-γ stimulation of 
epithelial cells from patients suffering from chronic rhinosinusitis 
downregulation of tight junction proteins and defects in epithelial cells were 
observed [80]. In skin, IFN-γ increased the apoptosis of keratinocytes [81].  
5.4.3.2 Th2 cells 
The development of Th2 cells from naïve T cells is driven by  
IL-4 [78, 82]. Since DC`s can`t produce IL-4, the main source of this cytokine 
are eosinophils, basophils, mast cells, NKT cells and germinal center B cells as 




its receptor on naive T cells, STAT6 is activated. Next, STAT6 promotes 
GATA3 expression, which is the master transcription factor of Th2 cells and 
activates the genes for the hallmark cytokines produced by Th2 cells: IL-4, IL-5 
and IL-13 [83]. Additionally, GATA3 stabilizes Th2 differentiation from naïve 
T cells by inducing its own expression. Th2 cytokines play major role in host 
defense against helminths. IL-4 and IL-13 are indispensable cytokines for 
immunoglobulin heavy chain class switch into IgE antibodies. Additionally, 
another Th2-related cytokine, IL-5 activates eosinophils and induces their 
differentiation and migration. Eosinophils express receptors for IgE and when 
the receptor is cross-linked by IgE Ab bound to the parasite, inflammatory 
mediators are released. Moreover, IL-4 and IL-13 contributes to alternative 
macrophages activation, stimulate peristalsis in the gastrointestinal track, 
increases mucin secretion from gut and airway epithelial cells, intestinal 
epithelial cells turnover, smooth muscle contraction [83-87], that collectively 
helps to facilitate the removal of parasites from the gut. On the other hand 
overproduction of type 2 cytokines may have detrimental effect mainly on 
allergic disorders like asthma, allergic rhinitis, atopic dermatitis, allergies to 
drugs and food [88]. Additionally, our recent data showed that IL-4 and IL-13 
disrupt epithelial cells tight junctions and might be responsible for impaired, 
leaky epithelial barrier in asthma (data not published).  
5.4.3.3 Th17 cells 
As soon as naïve T cells are activated by IL-6, TGF-β and IL-23 their 
differentiation is directed into Th17 cells [89-91]. Polarizing cytokines activate 
STAT3 transcription factor, which further induce orphan steroid receptor 
RORγt, a key transcriptional regulator of the Th17 cell fate [90, 92, 93]. The 
name of Th17 cells comes from the fact that the main cytokine produced by this 
subset is IL-17A and IL-17F. Furthermore, Th17 cells may produce IL-22 that is 




with TNF and GM-CSF, which provide the activation and recruitment of 
neutrophils [95].  Expansion of Th17 cells is promoted by IL-23 and Th17 cells 
are notably abundant in mucosal tissues. The main function of Th17 cells is 
induction of neutrophilic inflammation that recruits neutrophils to ingest and kill 
extracellular microbes. Nevertheless, pathogenesis of psoriasis, inflammatory 
bowel disease, rheumatoid arthritis and multiple sclerosis is associated with 
Th17 cells [96].   
5.4.3.4 Th9 cells 
Initially, IL-9 was characterized as a Th2 cell derived cytokine. Later,  
a separate Th9 subset of cells was defined. The differentiation of Th9 cells 
occurs in the presence of a signal delivered by TGF-β and IL-4 [97-99]. 
Interestingly, neither TGF-β nor IL-4 itself is sufficient to induce the Th9 profile 
with high levels of IL-9.  Development and maintenance of Th9 cells depends of 
IRF4 and PU.1, but so far, the master regulator of transcription has not been 
found [100, 101]. Both, protective as well as pro-inflammatory role for Th9 cells 
in mouse models and humans has been described. Protective immunity in 
infection with the parasitic worm N. brasiliensis [102], and in inhibition of 
subcutaneous [103] and pulmonary [104] melanoma growth was mediated by 
Th9 and Th9-derived IL-9. On the contrary, in EAE mouse model, IL-9 attracted 
pathogenic Th17 cells to the central nervous system via the induction of CCL20 
chemokine expression in astrocytes and induced EAE symptoms [105]. In the 
ovalbumin-induced model of airway inflammation, IL-9 neutralization strongly 
reduced allergic symptoms [100] and the transfer of OVA-specific Th9 cells into 
T-cell deficient mice caused asthmatic symptoms [101]. In humans, increased 
numbers of Th9 cells has been shown in the blood of allergic patients [106]. In 
summary, protective as well as inflammatory role for Th9 cells in mouse models 
and humans have been described. Figure 3 shows the main subsets of T helper 





Figure 3. Subsets of T helper cells (Adapted from [107]) 
 
5.4.3.5 Th22 cells 
5.4.3.5.1 IL-22 – gene, structure and signalling 
Interleukin-22 was discovered in 2000 as the “IL-10-related-T-cell-derived 
inducible factor (IL-TIF) in murine IL-9 stimulated BW5147 T lymphoma cells 
and discovered in human cells the same year [108-110]. IL-22 together with  
IL-19, IL-20, IL-24 and IL-26 are members of IL-20 subfamily of cytokines, 
which along with IL-10, IL-28A, IL-28B and IL-29 is a part of larger IL-10 
cytokine family [111]. Human IL-22 gene is located at chromosome 12q15 in 
the proximity of the genes encoding IFN-γ and IL-26 [109]. The other members 
of IL-20 subfamily, (IL-19, IL-20, IL-24) are located on chromosome 1q32. 
Mouse and human IL-22, a 179-amino acid protein, shares 79% homology and 
is encoded by a 537-base pair open reading frame [108]. Additionally, murine 




[108]. After removal of 33-amino acid signal peptide, a 146-amino acid protein 
in the active form is secreted [112, 113]. IL-22 is a monomer that may form 
non-covalently bound dimers and if present at high concentration tetramer are 
formed [113, 114]. As a monomer, IL-22 has a bundle-like structure that is 
composed of six α-helices and a small N-terminal helix stabilized by two 
intramolecular disulphide bridge bonds. Despite the fact that glycosylation has 
only a small effect on IL-22 tertiary structure, IL-22 has 3 potential 
glycosylation sites [113, 115].  
When produced, IL-22 binds to IL-22R, which consists of two subunits, 
IL-10R2 and IL-22R1 [116, 117]. IL-22R is a type 2 cytokine receptor with the 
typical structure consisting of an intracellular, transmembrane and extracellular 
moiety. STAT recruitment sites are located in the intracellular moiety  
of IL-22R1 rather than IL-10R2 [117]. The binding of IL-22 to IL-22 receptor is 
two-step process. In the first step IL-22 binds to the extracellular moiety of  
IL-22R1 as it has high affinity for IL-22R1 (Kd = 1-20nM) but no affinity to  
IL-10R2. The initial binding of IL-22 to IL-22R1 changes the conformation of 
the cytokine. In the next step IL-22/IL-22R1 complex binds to IL-10R2  
(Kd=7-45uM), which enables downstream signalling [116, 118-120]. 
Interestingly, both subunits of the IL-22 receptor may be used by other members 
of IL-10 cytokine family. IL-10R2 is a part of IL-10 receptor (IL-10R1/IL-
10R2), IL-26 receptor (IL-20R1/IL-10R2), IL-28 and IL-29 receptor  
(IL-28R1/IL-10R2) [121]. Meanwhile, the second IL-22 receptor subunit,  
IL-22R1, is used by IL-20 and IL-24 (IL-20R2/IL-22R1) and may mediate 
signalling and trigger effects similar to IL-22R [122, 123]. 
5.4.3.5.2 IL-22 receptor 
The binding of IL-22 to IL-22R1/IL-10R2 complex induces activation and 
phosphorylation of Jak1/Tyk2 tyrosine kinases that then phosphorylates tyrosine 




IL-22R1 attract STAT molecules, which are later phosphorylated by Jak1/Tyk2 
kinases [124]. Phosphorylated STAT3 is the key mediator of IL-22 function, 
however phosphorylation of STAT1 and STAT5 have also been reported. In 
addition to STAT mediated signalling IL-22 stimulation activates MAPK and 
PI3K-AKT-mTOR pathways as well [125]. 
It is well established that IL-22 is unique cytokine, which is produced by 
immune cells, acting solely on non-immune tissue cells. Cell sensitivity to IL-22 
is determined by expression of IL-22R1 subunit. The IL-10R2 subunit is 
expressed commonly in all cells, however IL-22R1 subunit is not detected on 
immune cells (monocytes, monocyte-derived macrophages, DCs, B cells, T 
cells, NK cells), but mainly on cells of epithelial origin in skin, small intestine, 
colon, liver, kidney, pancreas and lung [126, 127].  
Another level of regulation of IL-22 function is determined by existence 
extracellular IL-22-binding protein (IL-22BP). IL-22BP can be detected in 
normal tissues like thymus, spleen, lymph node, stomach, intestine, lungs, skin, 
placenta and breast [128-131]. The main cell subsets producing IL-22BP are 
immature dendritic cells. The production of IL-22BP by DCs decreases as soon 
as DC become mature [132, 133].  IL-22BP is a soluble, 210-amino-acid-long, 
secreted, single-chain protein that is encoded by the IL-22R1-independent gene 
[129, 131, 134, 135]. IL-22BP has 20-1000 times higher affinity to IL-22 than 
IL-22R1 [120]. Moreover, the part of IL-22 involved in binding with IL-22BP 
overlaps with the part of IL-22 that is engaged in binding to IL-22R1 [136, 137]. 
Taken together, IL-22BP has an inhibitory action towards IL-22 action by 
preventing the binding of IL-22 to IL-22R1/IL-10R2 complex.   
5.4.3.5.3 IL-22-producing cells 
The main producers of IL-22 are T cells and innate lymphoid cells 
(ILC`s). The first subset of T cells reported to produce IL-22 were Th1 cells 




to 35% are Th1 cells [138]. IL-22 and IFN-γ are localized closely on the 12th 
chromosome and it has been shown that IL-22 production correlates the best 
with IFN- γ production and T-bet expression [139]. Similarly, in mouse models, 
Th1 cells may produce IL-22 and the production can be upregulated by IL-12 
and synergistically acting with IL-18 [140].  
IL-22 is also secreted by Th17 cells. Most of controversy in the assigning 
IL-22 as Th17 rather than Th22 cytokine comes from discrepancy between 
mouse and human data. Among all mouse T helper subsets, Th17 cells are the 
major source of IL-22 and IL-22 is named as Th17 cytokine [141-143]. On the 
contrary, IL-22 production by human T cells does not correlate with either 
RORγT or IL-17A [139] and only 10-18% of IL-22-producing T cells co-
express IL-17A in the blood [138]. IL-1β, IL-6, TGF-β and IL-23, Th17 
polarizing cytokines differently influence IL-22 production by Th17 cells. In 
vitro stimulation of naive T cell with IL-6 alone, induces IL-22-single producing 
T cells, while the combination of IL-1β, IL-6 and IL-23 induces Th17 cells co-
expressing both, IL-17 and IL-22. On the contrary, IL-6 combined with TGF-β 
generate Th17 cells with little or no IL-22 production [144]. In summary, 
despite TGF-β, all Th17 polarizing cytokines promote IL-22 production. Indeed, 
it has been shown that TGF-β inhibits IL-22 production from murine Th17 cells 
through the c-Maf dependent mechanism [145].  
In human, the IL-22-only-producing T helper cells have been identified in 
peripheral blood mononuclear cells (PBMC`s) and defined as a separate  
T helper subset named Th22 cells [138, 146, 147]. 37% - 68% of all human  
IL-22-producing T cells in peripheral blood do not co-produce IFN-γ nor IL-
17A [138]. Despite the fact that, similar cells were reported in mice, the IL-22-
only-producing mice T cells have not been separated and defined as Th22 cells 
[148]. The common feature of Th17 cells and Th22 cells is that they share a 
requirement for IL-6. In the case of Th22 cells, TCR stimulation combined with 




Additionally, epidermal Langerhans cells, dermal DC`s, plasmacytoid DC`s 
promote the induction of Th22 cells [138, 149]. The Th22 cells express the 
pattern of chemokine receptors, mostly directing them to skin – CCR6, CCR4 
and CCR10, but do not express CXCR3 [138, 146, 147]. To some extent, Th22 
cells may have an autoreactive phenotype and react to auto-glycolipids 
presented on CD1a by Langerhans cells [150]. One of the possible reasons why 
IL-22-producing T cells are not completely defined as a separate Th22 subset is 
due to the lack of a key transcription factor responsible for induction of IL-22 
production. A promising candidate to fulfill this role is aryl hydrocarbon 
receptor (AhR). AhR is specifically expressed by Th17 cells, however AhR-
deficient T cells still differentiate into Th17 cells that lack IL-22 production.  
Nevertheless, AhR seems to be transcription factor that promotes IL-22 
production from Th17 cells rather than a bona fide Th22 cells transcription 
factor.  Further experiments have to be performed to completely understand the 
role of AhR induction of IL-22 in Th22 cells [151].  
Th1, Th17 and Th22 cells are not the only cells producing IL-22. As in 
case of CD4+ T cells, CD8+ T cells may produce either IL-17/IL-22 (Tc17) or 
IL-22 alone (Tc22). Human Tc22 cells differentiate from naïve cells upon IL-21 
stimulation [152] and similar to Th22 cells, TGF-β suppresses IL-22 and induces 
IL-17A production [153]. Identical Tc17 populations capable of producing  
IL-17 and IL-22 have been described in mouse models [154, 155]. Cells from 
the innate arm of immunity like γδ T cells, NKT cells and ILC3 cells may also 
produce IL-22. In case of γδ T cells, IL-22-producing cells express RORγt and 
IL-22 production is triggered in response to IL-23 and TLR`s ligands [156-158]. 
NKT cells have been reported also to produce IL-22 [159, 160]. NKT-IL-22-
producing cells just like αβ Tcells, γδ T cells and ILC3s express RORγt, IL-23R 
and CCR6. Further, IL-22 production by NKT cells, requires antigen 




It has been shown that in the Rag2-/- deficient murine gastrointestinal 
model of infection with Citrobacter rodentium, the level of IL-22 remain 
unchanged, despite the lack of all T and B cells [162]. In mouse models of 
infection, at the later stages of infection Th22 cells are the main source of IL-22 
while during the early phases ILC3s are the main producers of IL-22. After 
years of research, it turns out that the dominant source of IL-22 in the 
gastrointestinal track are ILC`s group 3 [163-166].  
Recently, it has been described that neutrophils contribute to antimicrobial 
defense and reconstitute epithelial integrity during colitis by IL-22 production 
[167]. Surprisingly, Mashiko et al. reported that mast cells are the major IL-22-
producing cells found in patients with psoriasis and atopic dermatitis [168].  
5.4.3.5.4 Effect of IL-22 on tissue cells 
In general the effect of IL-22 on epithelial cells in the gut, skin and lungs 
can be divided into five main effects. First of all IL-22 increases innate defense 
mechanisms against microbes via the induction of antibacterial proteins  
(β-defensins, members of S100A family, regenerating islet-derived protein 
(REG) family members) and mucus associated proteins [162, 169-171]. 
Secondly, especially in the skin, IL-22 influences keratinocytes differentiation 
by reducing the expression of keratins, profilaggrins, kallikreins, desmocollins, 
proteins, which are necessary for keratinocytes terminal differentiation [171, 
172]. Similar effects can be observed in epithelial cells from the gut and 
respiratory track where IL-22 inhibits cell differentiation but at the same time 
enhances their proliferation [173]. Furthermore, production of chemokines, 
mostly neutrophil attracting chemokines like CXCL1, 2, 5, 8 are increased in 
keratinocytes stimulated with IL-22 [169]. In addition, increased expression of 
extracellular matrix degrading enzymes (Matrix metalloproteinase 1 and 3 - 
MMP1 and MMP3) was promoted by IL-22 and by the enhanced migratory 




positive feedback loop and increased expression of IL-20, which binds to IL-
22R1/IL-20R2, and increase expression of STAT3, main molecule of 
intracellular signal downstream of IL-22R [174, 175], (Figure 4.) On the 
contrary, when uncontrolled, IL-22 primary helpful function may lead to 
pathology. In the next chapter the main pathological functions of IL-22 in 
different diseases will be discussed. 
Psoriasis 
Psoriasis is the first immune mediated disorder that has been associated 
with inflammatory IL-22 function [127]. IL-22 expression is upregulated in 
lesional skin as compared to non-lesional psoriatic and healthy skin [127]. The 
anti-psoriatic therapy significantly decreases IL-22 expression in lesional skin 
[171, 176]. Among all IL-22-producing cells in psoriasis the majority are dermal 
CD4+ T cells including Th22 and Th17 and to lesser extent Th1 cells [177]. On 
the contrary, in the epidermis the number of Tc22 that do not produce IFN-γ and 
IL-17 was also increased [178]. On the contrary to IFN- γ and IL-17, cytokines 
that are highly expressed in lesional skin, only levels of IL-22 increases in blood 
of psoriatic patients and correlate with disease severity [171]. The pathological 
influence of IL-22 on keratinocytes includes, epidermal hyperplasia caused by 
altered terminal differentiation, secretion of granulocyte chemoatracting agents 
that accumulate neutrophils in psoriatic lesion and finally, induction of IL-22 
production and STAT3 expression [172, 175]. Interestingly, despite the 
dysfunctional epithelial barrier, psoriatic skin is resistant to bacterial infection, 
mainly due to the induction of anti-microbial peptides production by IL-22 
stimulated keratinocytes [171]. The effect of IL-22 on keratinocytes 
differentiation is IL-22-specific and neither IL-17 nor IFN-γ influence or 
amplify this action [175, 179]. However, IL-17 and IFN-γ may only strengthen 
IL-22 induced production of antimicrobial peptides, cytokines and chemokines 




increased. Cytokines produced locally in psoriatic skin, mainly IFN-α and  
TNF-α, additionally upregulated IL-22R1 expression and amplify the effect of 
IL-22 [175, 180, 181].  
 
Atopic dermatitis 
IL-22 is also elevated in the inflamed skin of atopic dermatitis (AD) 
patients [127]. Compared to psoriasis, the main producers of IL-22 in AD are 
Th22 and Tc22 cells capable of co-expressing IL-13 [177, 182]. The chronic 
form of AD is characterized by the conversion of immune responses from Th2-
mediated to Th1/Th2/TH22 mixed responses. Often, patients with AD suffer 
from cutaneous infections since other cytokines, like IL-17 are not expressed 
and cannot cooperate with IL-22 in the induction of antimicrobial peptides. 
Levels of IL-22 in the serum correlates with the expression of CCL17,  
a chemokine that attracts T cells expressing CCR4 to skin of AD patients [183].  
Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is chronic inflammatory disease of 
gastrointestinal track that is subdivided into 2 forms: ulcerative colitis (UC) and 
Crohn`s disease (CD). In inflamed intestines of both forms of IBD, increased 
expression of IL-22 is detected [184]. In patients with UC, IL-22-producing T 
helper cells are mostly located within the lamina propria, while in CD patients 
Th22 cells are detected throughout the intestinal wall, and higher numbers of 
Th22 cells are present in CD as compared to UC patients [184]. Additionally to 
local tissue expression, IL-22 is detected in the blood of CD patients and 
correlate with disease severity [185]. IL-22 is considered to play a protective 
role in IBD by acting on intestinal epithelial cells and inducing: production of 
antimicrobial peptides (Reg family of c-type lectins, defensins, cathelicidins) 




molecules and reconstitution of the mucus-producing goblet cells [187], 
epithelial cells proliferation that contributes to the regeneration and repair of 
epithelial layers [188]. It should be taken into account that despite this protective 
role of IL-22 in IBD, amplification of intestinal inflammation by IL-22 was 
reported in a colitis model induced by transferring CD45Rb
low
 CD4+ memory 
IL-10-deficient T cells [189]. 
Lung inflammation and asthma 
An increased levels of IL-22 mRNA and protein have been reported in the 
blood of asthmatic patients and in murine asthma models [190, 191]. IL-22 has a 
dual role in asthma-associated lung inflammation [191]. When administrated 
during allergen challenge, IL-22 reduced the expression of Th2-derived 
cytokines and chemokines, eosinophils infiltration and airway constriction. 
Consequently, neutralization of IL-22 exacerbated lung inflammation and 
pathology. On the contrary, the role of IL-22 during the sensitization phase 
depends on the route the allergen was applied. Subcutaneous sensitization of IL-
22 exhibits a pathologic role and exacerbated lung inflammation as compared to 
intraperitoneal sensitization [192-194]. Inhibition of CCL17 and IL-25 
production, minimizes lung cell damage and the possible involvement of IL-10 
could play a potential role in the dual function of IL-22 in lungs [192, 194].  
Additionally, the lung is an organ where the role of IL-22 depends on the 
other cytokines present in the inflamed airways. In the model of bleomycin-
induced fibrosis, in the presence of IL-17A, IL-22 contributes to airway 
inflammation while in the absence of IL-17, IL-22 exhibits a tissue protective 
role [195]. 
Rheumatoid arthritis  
In general IL-22 targets only epithelial cells, however synovial tissue 




synovial tissues and cells from the synovial fluid of patients with rheumatoid 
arthritis (RA), high levels of IL-22 mRNA were reported [196]. IL-22 is 
increased not only in synovial tissue but also in the serum of patients with RA, 
where the increased number of Th22 cells can be observed [197-199]. Levels of 
IL-22 in serum correlated with disease severity and progression [197, 199]. By 
inducing proliferation of synovial fibroblasts, IL-22 contributes to the pathology 
of RA [196]. Moreover, IL-22 stimulated fibroblasts produce CCL2 and 
RANKL production from fibroblasts, which attract monocytes to the synovium 
and induces their differentiation to osteoclasts, respectively [196, 200].  
Hepatitis 
Hepatocytes are the main targets of IL-22 in the liver. The protective role 
of IL-22 in liver inflammation was shown in mouse models, where IL-22 
prevented: 1) concavalin-A induced liver injury, necrosis and apoptosis via  
IL-22-dependent STAT3 activation and induction of anti-apoptotic proteins 
[201], 2) hepatocyte necrosis during Salmonella infection [202] and general 
liver pathology and lethality in malaria infection [203], 3) liver ischemia-
reperfusion injury [204], 4) acute as well as chronic alcohol induced liver 
damage [205].  In general, IL-22 action in liver mainly relies on: induction of 
acute-phase proteins (Amyloid A, α1-antichymotrypsin, haptoglobin, LPS-
binding protein) and anti-apoptotic proteins production from hepatocytes [127, 
185, 206] and promotion of liver stem/progenitor cells proliferation [207].  
Pancreatitis 
 The pancreas is the organ where tissue expression of IL-22R1 is the 
highest among all organs [127]. Within the pancreas, IL-22R1 is expressed by 
acinar and islet cells [208, 209]. The therapeutic potential of IL-22 in 
pancreatitis has been suggested [210-212]. The main protective effect was 




and Bcl-XL anti-apoptotic proteins by acinar cells. Additionally, islet cells may 
produce Reg1 and Reg2 molecules and increase proliferation upon IL-22 
stimulation, which may contribute to overall protective effect of IL-22 in 
pancreatitis [210-212]. 
 
Host defence against microbial infection 
The initial work of Graham et al. showed that IL-22 is not essential in the 
immunity against the intracellular pathogen Listeria monocytogenes [213]. 
Moreover, in mice, IL-22 is unnecessary for host defence against intracellular 
pathogens during intravenous infection with Mycobacterium avium [214], 
intraperitoneal infection with Salmonella enterica intratracheal [202] and during 
intra-tracheal infection with Francisella tularensis [215]. Based on this 
observation and the fact that IL-22 induces production of antimicrobial peptides 
from epithelial cells, it became clear that the major function of IL-22 is the 
control of extracellular bacteria.  
In the mouse model of Citrobacter rodentium infection that specifically 
infects epithelial cells in the murine colon, which is normally a self-resolving 
infection, but in IL-22-deficient mice turned deadly within the second week 
post-infection. In this model, IL-22 contributes to host defence mainly by 
inducing anti-microbial Reg peptides (RegI, RegII, RegIIIα, RegIIIβ, RegIIIγ, 
RegIIIδ) production from epithelial cells [162]. In addition, IL-22 is involved in 
the resistance against pulmonary infection with gram-negative bacterium - 
Klebsiella pneumonia, since neutralization of IL-22 resulted in death of animals 
within 24 hours post infection. Here, IL-22 together with IL-17 induces the 
expression of cytokines, chemokines and lipocalin-2 that directly kills bacterium 
[169]. Finally, beneficial role of IL-22 in control of infection was shown for 
Staphylococcus aureus infection in the skin and lung [216] as well as for 




 Role of IL-22 in immunity against fungal infection was also investigated. 
First of all, in a model of lung infection with Aspergillus fumigatus, IL-22 
contributes to the protective immunity and control of fungal burden in a Dectin-
1/IL-23 dependent manner [218]. Secondly, IL-22 is induced in the stomach of 
mice infected with Candida albicans via an intragastric route, and is 
indispensable in preventing the dissemination of C.albicans to the stomach and 
kidney [219].  On the contrary, IL-22 has a minor role against Candida infection 
when the yeast is applied via the oropharyngeal route [220] or in the skin model 
[221]. In humans, role of IL-22 in control of Candida albicans infection is not 
clear. It has been reported that, patients that have high titre of anti-IL-22, anti-
IL-17A and anti-IL-17F auto-antibodies are susceptible to develop chronic 
mucocutaneous candidiasis (CMC) [222]. 
Similarities between IL-22 and type III interferons (IL-28A, IL-28B,  
IL-29) in terms of sharing common receptor subunit IL-10R2 and acting on the 
same cells, suggested that IL-22 may play a role in anti-viral immunity [121]. 
Indeed, in influenza virus infection mouse model, IL-22 plays a role in 
protection of tracheal epithelial cells and additionally prevents secondary 
bacterial infection with S. aureus [216, 223]. However, IL-22 does not act 
directly on the virus, but rather limits tissue damage caused by virus [223]. In 
human immunodeficiency virus (HIV) infection in humans, in the chronic phase, 
reduction of Th22 cells is observed and it correlates with loss of epithelial cell 
integrity. As a result, chronic immune activation is induced by increased 


















5.5 Immunology of palatine tonsils. 
Palatine tonsils (PTs) are a part of mucosa-associated lymphoid tissue 
(MALT) in the human pharynx named the Waldeyer`s ring [225]. Besides 
palatine tonsils Waldeyer`s ring consist of: nasopharyngeal tonsil (adenoid - 
attached to the roof of the pharynx), paired tubal tonsils (at the openings of the 
Eustachian tubes) and lingual tonsil (at the back of the tongue) [226]. 
Considering the fact that PTs are easily accessible, palatine tonsils are the best 
studied among all tonsils. Palatine tonsils are positioned in the entry of 
respiratory and gastrointestinal tracks, the place where, just before they are 
exposed to digestive enzymes and acidic gastric secretion, foreign antigens and 
substances from food and air come into contact with the mucosal tissues. This is 
the strategic region where the immune responses against diverse antigens that 
enter the body through the mouth and nose are initiated [227]. Adenoids as well 
as palatine tonsils may be removed, however fully functional lingual and tubal 
tonsils might take over their role [228]. The characteristic feature of palatine 
tonsils is the formation of deep tubular crypts, that extends the external surface 
of tonsil up to 300 cm2 [229]. Long-term contact with antigens and direct 
stimulation of immune cells with food and air-born allergens is possible due to 
highly cryptic surface. The outer surface of the palatine tonsils is covered by a 
stratified squamous non-keratinized epithelium. Contrary to this, the epithelium 
of crypts is called lymphoepithelium, as it is infiltrated with non-epithelial cells, 
mainly lymphocytes [226]. In the reticulated epithelium, cells, which are 
functionally matching intestinal M-cells were found [230]. As they possess 
remarkable potential to transcytose a broad range of particles and soluble 
material without their degradation, they translocate antigens to subepithelial 
lymphoid tissue [231]. Immune cells, mainly lymphocytes are found in all the 
compartments of the tonsils including the lymphoepithelium (the intraepithelial 
leukocytes - IELs), the inter-follicular regions and the follicles. Among all IELs, 




T cells. Similarly, the secondary lymphoid follicles are mainly populated by B 
cells; intense maturation and differentiation takes place there. Beside B cells in 
the germinal center of follicular T cells and follicular DC`s are found [226, 232]. 
Interestingly, recently McClory et al. identified 5 tonsillar T cell developmental 
intermediates and proved that each of them resembles its thymic counterpart. 
With this work it has been proven that full stepwise program of T cells 
development may take place in human tonsils [233]. Moreover, tonsils have 
been shown as the potential first-line organ involved in tolerance via generation 
of allergen specific FOXP3+ T regulatory cells [228]. As described above, from 
immunological point of view palatine tonsils are very interesting organs but yet 






















5.6 microRNAs - biogenesis and function 
Human genome studies have revealed that only a small fraction of 
transcribed genes is further translated and all non-coding transcripts are named 
as ncRNA (non-coding RNA) [234, 235]. ncRNA has been organized into the 
groups based on their position in genome, function or length of the transcript. 
The division based on the length of the transcript divides ncRNA into: small and 
long ncRNA. The group of small ncRNA consists of: 1) microRNAs (18–25 nt), 
2) small-interfering RNAs (19–23 nt), 3) piwi-interacting RNAs (26–30 nt), 4) 
small nuclear and nucleolar RNAs (60–300 nt), 5) promoter-associated small 
RNAs (20–200 nt), 6) transcription initiation RNAs (18 nt), 7) centromere 
repeat-associated small interacting RNAs (34–42 nt), 8) telomere-specific small 
RNAs (24 nt), and 9) pyknons (variable in size) [236].  
Discovered for the first time in Caenorhabditis elegans [237] almost 20 
years ago, microRNAs are nowadays recognized as posttranscriptional gene 
expression regulators.  Genes coding microRNAs are mostly non-coding genes 
from, which the only product is the miRNA. Additionally, miRNA genes may 
be located within un-translated regions of a protein coding genes or gene 
intrones [238]. MicroRNA genes are transcribed by RNA polymerase II into 
primary the miRNAs transcript (pri-miRNAs) [239]. As it happens for the 
protein coding mRNA, the pri-miRNA is spliced, capped and polyadenylated 
[240]. The primary miRNA transcript is converted into active miRNA in two 
endonuclease dependent steps. During the first step, pri-miRNAs are bound to 
mRNA binding protein - DGCR8, which is associated with the Drosha enzyme 
[241]. Ribonuclease III (RNase III) activity of Drosha enzyme cleaves flanking 
sequences of pri-miRNA and releases hairpin structures known as precursor 
miRNA (pre-miRNAs) [242]. Next, pre-miRNA is exported from the nucleus to 
the cytoplasm by Exportin-5 [243]. The second step, which takes place in the 
cytoplasm, RNase III Dicer cleaves off the hairpin loop of the pre-miRNA, and 




and one of single stranded miRNA join with Argonaute (AGO) proteins from 
miRISC, the miRNA-induced silencing complex. The other strand, which does 
not form miRISC, is typically degraded. Nevertheless, in case of some miRNAs, 
both strands of mature miRNA can be loaded into miRISC. The strand from 3` 
end of hairpin is named “3p” and from 5` end is named “5p” [245]. The core of 
miRISC, formed by mature miRNA bound to AGO proteins, seeks for target 
mRNA to which mature miRNA is specific. The major determinants of target 
mRNA recognition are located in the “seed region” in the position 2-8 from the 
5` end of miRNA. However, the 3` end of miRNA can contribute to target 
recognition as well [246]. Depending on the location of complementarity, the 
mRNA target may be cleaved directly by the endonuclease activity of AGO – 
complementarity in central region, or other protein complexes, like GW182, 
CCR4-NOT, may be recruited to miRISC to remove poly (A) tail, what leads to 
translational repression and increased mRNA degradation [247, 248].  
5.6.1 MicroRNA in T cells function and differentiation 
Specific patterns of miRNA expression in murine haematopoietic system, 
which have been identified in systemic mRNA profiling studies, proposed that 
miRNAs may have a role in development and effector function of cell lineages 
[249]. Since then, extensive profiling of naïve, activated and differentiated 
human CD4+T cells took place [250]. As predicted, decreased survival and 
proliferation of T cells upon activation was observed in T cells where Dicer or 
Drosha enzymes as well as DGCR8 subunits were deleted [251, 252]. However, 
increase cytokine production and differentiation into T helper cells was observed 
in miRNA deficient CD4+ T cells, suggesting that miRNA may be important in 
maintenance of T cells in the naïve state [252]. Similarly, with a few exceptions 
namely miR-155 and group of miR-17-92 were induced, most of miRNAs that 
are expressed in resting T cells are downregulated after T cells activation [253]. 




miRNA binding sites are lost, that as a result protects target mRNA from 
miRNA-mediated degradation [254]. MiR-29ab, miR-146a, miR-155 and are the 
best studied miRNAs in T cells [255]. 
The role of miR-17-92 gene cluster was studied in detailed in PI3K 
signalling during T cell activation and signal transduction. In mouse models 
where miR-17-92 cluster was overexpressed during thymocyte development, 
CD4+ T cells expanded and mice developed systemic autoimmunity. The main 
effect was observed because miR-17-92 promotes CD4 T cells proliferation in 
response to TCR stimulation and inhibits activation induced cell death without 
the need for co-stimulation signals provided by CD28-CD80/CD86 interactions 
[256, 257].  
The other known regulator of T cell signalling that has an effect on T cells 
development is miR-181. Inhibition of miRNA-181 in thymocytes impaired T 
cells selection and decreased TCR sensitivity. Oppositely, overexpression of 
miR-181 in mature T cells reduces TCR threshold for activation and increases 
sensitivity to presented antigens in the periphery [258].  
During antigen recognition and T cells activation, IL-2 produced by T 
cells function in the autocrine manner to promote cells proliferation.  
Regulation of downstream signalling of IL-2R by miRNA-182 has been 
described. miR-182 enhances clonal selection by inhibiting FOXO1, the T cell 
proliferation limiting transcription factor that is highly expressed in naïve T cells 
[259]. On the contrary miRNA-146a negatively regulates IL-2 production in T 
helper cells [260]. Reduction of IL-2 production and inhibition of cell activation 
occurs as well when miR-181d directly targets IL-2 mRNA in T helper cells 
[261]. miR-184 and miR-31 instead of directly targeting IL-2 mRNA, regulate 
the main IL-2 transcription factor – NFAT and inhibits – miR-184 or activates – 







Figure 5. Biogenesis of microRNA (adapted from [264]) 
 
5.6.2 Role of miRNAs in Th1, Th2 and Th17 cell 
differentiation 
The most potent, direct inhibitors of Th1 differentiation and IFN-γ 
production are miR-29a and miR-29b [265]. T-bet, the key transcriptional factor 
of Th1 cells and Eomes, the regulator of IFN-γ production, both are targeted by 
miR-29a/b, that results in the inhibition of IFN-γ production [266]. Interestingly, 
miR-29 can directly target mRNA for IFN-γ [266, 267] as shown in in vivo 
infection with Listeria monocytogenes and Mycobacterium bovis models. In the 
models mentioned above, IFN-γ production and miR-29 expression negatively 
correlated in natural killer as well as T cells [266]. Additionally mice expressing 




miR-29a levels, controlled Listeria monocytogenes infection due to increased 
IFN-γ production from T cells [267]. Nevertheless, miR-29a was induced by 
IFN-γ, in the process of negative feedback loop that may play a role in 
autoimmune diseases [267].  
Other various miRNAs may indirectly influence Th1 cells differentiation. 
CD4+ T cells deficient in miR-146a produce more IFN-γ as compared with non-
manipulated cells. The main effect of miR-146a is the regulation of STAT1, 
Traf6 and Irak1 [268, 269]. On the contrary, miR-155 enhances Th1 mediated 
immunity, mainly by inhibiting SOCS1 (Suppressor of cytokine signalling 1) 
and SHIP-1 molecules involved in suppression of cytokine signalling [270, 271]. 
It has been shown that in mice deficient in miR-155, polarization and 
differentiation of T helper cells is directed into Th2 cells with high levels of IL-4 
and IL-5 [272, 273]. miR-155 targets directly the activator of IL-4 promoter, 
however the promotion of Th1 cells by miR-155 takes place only in the absence 
of Th2 polarizing cytokines [273]. miR-17-92 cluster is another activator of 
human Th1 differentiation. Under Th1 polarizing conditions, naïve transgenic 
CD4+T cells produced large amounts of IFN-γ [257] and the deletion of miR-
17-92 resulted in reduction of IFN-γ secreting Th cells [256].  
The indirect effect of microRNA`s on differentiation of Th1 cells is 
delivered by miR-21, which modulates IL-12 production by dendritic cells and 
thereafter regulates Th1 responses. miR-21 directly targets mRNA for the  
IL-12p35 subunit. Increased IL-12 production by DC`s is observed in vivo with 
miR-21 deficiency, that results in enhanced Th1 development and delayed-type 
hypersensitivity responses [274].   
As compared to regulation of Th1 differentiation by miRNAs, regulation 
of Th2 differentiation is less well understood. Th2 polarization of mouse CD4+ 
T cells is promoted by miR-126 via direct targeting of POU2F3 – the activator 
of the PU.1 transcription factor [275]. Moreover, inhibition of miR-126 reduced 




expression of miR-126 in the airway wall was reported. Interestingly, 
administration of the antagomir, which directly targets miR-126 decreased AHR 
(airway hyper-responsiveness) and recruitment of eosinophils to lungs [275].  
In the microRNA overexpression experiments it has been shown that Th2 cells 
differentiation may be affected. Overexpression of miR-21 increased Th2 
differentiation, however overexpression of miR-27 and miR-128 decreased 
secretion of Th2-related cytokines by activated T helper cells [276, 277].  
Polarization of naive T cells into Th17 cells is enhanced mainly by miR-
155, miR-301 and miR-326. In the murine model of experimental autoimmune 
encephalomyelitis (EAE) and in patients with multiple sclerosis, expression of 
miR-326 was up-regulated in CD4+ T cells and correlated positively with 
disease severity and IL-17A mRNA expression [278]. Furthermore, direct in 
vivo targeting of miR-326 with “sponge miRNA” reduced severity of EAE in 
mice. Similarly, in vitro blocking of miR-326 reduced Th17 cell differentiation. 
Mechanistically, Ets1 – the main negative regulator of Th17 cells differentiation 
is directly targeted by miR-326, which leads to increase Th17 cells 
differentiation [278].  
It has been reported that CD4+ T cells from mice with EAE expressed 
enhanced levels of miR-155. As expected, miR-155-deficient mice showed less 
inflammation, fewer Th17 cells in the brain and other tissues, and were resistant 
to EAE [279, 280]. Beyond contributing to Th17 mediated autoimmune diseases 
in the T cell dependent manner, miR-155 stimulates production of Th17 
polarizing cytokines, IL-6, IL-21, and IL-23, by activated dendritic cells [280]. 
Additionally, defective Th17 cell responses in mice lacking miR-155 made them 
resistant to collagen induced arthritis as well as chronic gastritis and colitis in 
response to Helicobacter pylori [281, 282]. In summary, as described in 





Finally, the last known miRNA that promotes Th17 cells differentiation is 
miR-301a. Through targeting Pias3, inhibitor of STAT3 transcription factor 
critical for IL-6 and IL-23 induced Th17 cells development, miR-301a drives 




























6.1 Increased microRNA-323-3p in IL-22/IL-17-producing 
T cells and asthma: a role in the regulation of the TGF-β 
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IL-22- and IL-17-producing T cells have important roles in allergic diseases. 
MicroRNAs (miRNAs) are post-transcriptional gene expression regulators, 
which modulate numerous biological processes, including immune responses in 
allergic diseases. There is little known about the functions of miRNAs in  
IL-22/IL-17-producing T cells. 
Material and Methods:  
IL-22- and IL-17-positive T cells were sorted from human peripheral blood 
mononuclear cells (PBMCs) by means of intracellular staining. miRNA 
expression profiles were detected with TaqMan array microfluidic cards. For 
functional studies, T cells and human embryonic kidney 293 cells were 
transfected with miRNA mimics. The expression of miRNAs and protein coding 
genes was analyzed using RT-qPCR and/or enzyme-linked immunosorbent 
assay in T cell subsets, T cell culture supernatants and PBMCs from patients 
with asthma and atopic dermatitis.  
Results:   
The increased expression of miR-323-3p and non-coding RNA nc886 and the 
reduced expression of miR-146a, miR-93, miR-181a, miR-26a and miR-874 
were detected in IL-22-producing T cells. The pathway analysis of the putative 
targets suggested that these differentially expressed miRNAs could impact the 
proliferation, differentiation and effector functions of T cells. Further analyses 
showed enhanced expression of miR-323-3p in both IL-22- and IL-17-positive T 
cells and its capacity to suppress IL-22 production in T cells. Multiple genes 
from the transforming growth factor β pathway were identified as direct targets 
of miR-323-3p. An increased expression of miR-323-3p was observed in 





Our data suggest that miR-323-3p may play a role in the regulation of IL-22 






T helper (Th) 17 cells are characterized by the expression of interleukin 
(IL)-17A (referred to as IL-17 in this study) and IL-17F [284, 285].  Depending 
on the environmental effectors, Th17 cells can also produce different amounts of 
IL-22, IFN-γ, IL-10 as well as other cytokines. For example, in the presence of 
transforming growth factor (TGF)-β, Th17 cells are known to produce more  
IL-10 and in the absence of TGF-β more IL-22 [286]. More recently, a distinct T 
cell-subset producing IL-22, but not IL-17 or IFN-γ, was defined [287, 288] and 
was found to play roles in the immune responses of the skin including the 
pathogenesis of atopic dermatitis (AD) [147, 177]. IL-22 has been shown to 
suppress antigen-induced airway inflammation in mice while being linked to 
tissue protection and regeneration [284, 285, 289]. IL-17 has been demonstrated 
to be central in neutrophilic airway inflammation [290, 291].  
MicroRNAs (miRNAs) are post-transcriptional regulators of gene 
expression that mainly cause gene silencing by the degradation of target mRNAs 
and the inhibition of translation [292].  The function of numerous individual 
miRNAs has been demonstrated in the regulation of differentiation, phenotypic 
stability and plasticity of T cells [264]. For instance, the differentiation of Th17 
has been shown to be dependent on the transcription factor retinoic acid 
receptor-related orphan receptor γt (RORγt) [92], as well as on several miRNAs, 
such as miR-155 [280], miR-10a [293] and miR-326 [278]. Recent studies 
demonstrate that miRNAs also play important roles in the regulation of immune 
responses in allergic diseases [294-296], which partially might be due to the 
impact on differentiation, phenotypic stability and plasticity of T cells [264]. 
The role of miRNAs in the development and regulation of IL-22-producing T 
cells have not been described previously. 
 In the present study, we analyzed the expression of miRNAs in IL-22-
positive T cells and peripheral blood mononuclear cells (PBMCs) from patients 




IL-22/IL-17-producing T cells, its capacity to suppress multiple factors from the 
TGF-β pathway and IL-22 production in T-cells from heathy donors.  
In addition, we report increased expression of miR-323-3p in the peripheral 
























MATERIALS AND METHODS 
Study participants 
This study was approved by the Ethical Review Committee on Human 
Research of the University of Tartu. All participants provided a signed informed 
consent form. None of the patients or control individuals was under the 
treatment with anti-histamines or systemic corticosteroids either currently or 
within three weeks prior to the study. Patients with pulmonary physician-
diagnosed asthma according to the Global Initiative for Asthma 
(www.ginasthma.org) aged below 55 years were included. Eight out of 10 
patients with asthma had known allergies, 9 out of 10 used inhaled 
corticosteroids on a regular basis. Seven out of 10 patients included with 
dermatologist-diagnosed AD (age range 21-58) had the confirmed diagnosis of 
the allergic type of AD based on an increased level of IgE. All patients with AD 
had an exacerbation with 1-2-week duration prior to their recruitment into the 
study. The control individuals were randomly selected from the general 
population of the same age and were free of allergic diseases.  
Isolation of PBMCs 
Human PBMCs were isolated from the peripheral blood of healthy adult 
volunteers or patients with asthma or AD by using density gradient 
centrifugation on Ficoll (Biochrom, Berlin, Germany), as described previously 
[297, 298]. 
Intracellular staining and cell sorting  
Human PBMCs were cultured in supplemented RPMI-1640 (cRPMI) 
medium for 3 days as described previously [297] in the presence of 20 µg/ml 
TLR3 ligand Poly I:C (Sigma-Aldrich ), IL-7 (40 ng/ml), and IL-23 (10 ng/ml). 
On day 3, the cells were stimulated with PMA (25 ng/ml) and Ionomycin  




with fixable viability dye eFluor 780 (eBioscience, Aachen, Germany) and 
PerCP-Cy5,5-conjugated anti-CD3 (Biolegend San Diego, CA, USA). Then, the 
cells were permeabilized using cytofix/cytoperm kit (BD Biosciences, Franklin 
Lakes, NJ, USA) according to manufacturer’s instructions, stained 
intracellularly with mouse anti-human PE-conjugated anti-IL-22 antibody 
(eBioscience) and with Alexa Fluor 488-labeled mouse anti-human IL-17A Ab 
(Biolegend), and sorted by a BD FACSAria™ II.  
miRNA profiling 




cell for each sample was 
extracted using a miRNAeasy Mini Kit (Qiagen, Valencia, CA, USA) in the 
presence of 0.8 µg of MS2 carrier RNA (Roche, Basel, Switzerland). Reverse 
transcription (RT) with Megaplex™ Primer Pools (Human, A v2.1), pre-
amplification of RT products with Megaplex™ PreAmp Primers (Human Pool 
A, v2.1) and miRNA profiling with TaqMan® Array Human MicroRNA.  
A microfluidic Cards (v2.0) were performed using the 7900HT Fast Real-Time 
PCR System (Life Technologies, Grand Island, NY, USA) and analyzed 
according to manufacturers’ instructions. A total of 68 miRNAs detected with a 
cycle value of less than 30 were subjected to further analysis. The data were 
normalized against miR-19b. Arbitrary units were calculated according to the 
following formula: arbitrary units = 2
–ΔCt
 × 10.000. 
miRNA target selection and pathway analysis 
miRNA targets containing miRNA binding sites with a total context score 
of less than -0.2 and the targets conserved among vertebrates were selected 
using Targetscan 6.2 [299]. Out of the selected targets, only the genes expressed 
in unstimulated CD4+ cells (9,539 genes with detection P-value of P<0.05 
according to A-MEXP-1173) were subjected to the pathway analysis. Pathway 
analysis was performed with g:Profiler (http://biit.cs.ut.ee/gprofiler), which 




Encyclopedia of Genes and Genomes (KEGG) pathways and enables one to 
estimate significance of the search results by calculating the enrichment P-value 
with the one-tailed Fisher's exact test [300].  
Luciferase assay 
300-500 nt long 3’ untranslated region fragments of SMAD2, SMAD3, 
SMAD5 and CDKN1B were PCR-amplified using human genomic DNA as a 
template and cloned into the pmirGLO Dual-Luciferase miRNA Target 
Expression Vector (Promega, Madison, WI, USA) in NheI and SalI sites. The 
following primers were used: SMAD2 For 5’-ATT GCT AGC GTG GAA TCT 
GTT TCC TAT AT-3’, SMAD2 Rev: 5’-ATT GTC GAC CTA CAG GAA 
AAT CTG CTT CT-3’, SMAD3 For: 5’-ATT GCT AGC GTC TTC ACA ATG 
TAT TTT CAT CA-3’, SMAD3 Rev: 5’-ATT GTC GAC CAG AGG ACC CTT 
GTG GA-3’, SMAD5 For: 5’- ATT GCT AGC GCA TAT ACA GTG AAG 
AGT AA-3’, SMAD5 Rev: 5’-ATT GTC GAC GCA TCT AAG TCC AAG 
TCC AAG TCA C-3’, CDKN1B For: 5’-ATT GCT AGC GAT AAG TGA 
AAT GGA TAC TAC AT-3’, CDKN1B Rev: 5’-ATT GTC GAC CTT TAT 
TGA TTA CTT AAT GTG TAA c-3’, CDKN1B II For: 5’-ATT GCT AGC 
GAT GTA GCA TTA TGC AAT TAG G-3’ and CDKN1B II Rev 5’-ATT GTC 
GAC CAG CTA TCT AAC AAA CTT TAG AT-3’. The transfections were 
carried out in 24-well plates using 0.8 µl of siPORT NeoFX (Life technologies, 
Grand Island, NY, USA), 30 nM of mirVana® miRNA mimics hsa-miR-323a-
3p and a Negative Control #1 (Life Technologies), 50 ng of the reporter 
plasmid, and 2x10
4
 human embryonic kidney epithelial 293 cells in 0.6 ml 
medium for 24 hours. Firefly and renilla luciferase activities were measured 
using Promega dual luciferase assay and firefly luciferase activities were 
normalized to the values of the renilla luciferase.  




T cells were isolated from frozen healthy blood donors’ PBMCs using 
Dynabeads Human T-Expander CD3/CD28 (Life Technologies, Carlsbad, CA, 
USA) beads, according to the manufacturer’s protocol. Briefly, PBMCs were 
thawed with adding warm TexMACS Medium (Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany), suspended, centrifuged and washed with 1% of 
bovine serum albumin (BSA) in phosphate buffered saline (PBS). After that, the 
cells were counted, mixed with Dynabeads in a 1:1 ratio in the total volume of  
1 ml 1% BSA in PBS and rotated at 1 rpm for 30 minutes at 4°C. The bead-
bound cells were collected in the magnetic field, resuspended in TexMACS 
medium, counted and incubated at 37°C for 24 hours prior the transfection. The 
transfection was performed with Neon electroporation transfection system (Life 
Technologies, Grand Island, NY, USA) according to the manufacturer’s 
protocol with minor modifications. Transfections were performed using 2-4 x 
10
7
 cells/ml and miRNA concentration of 500 nM in 10 μl “R buffer” (Life 
Technologies) and the Neon transfection system setting 1,550V with three  
10-ms pulses. Pre-miR™ Precursors Molecule hsa-miR-146a and mirVana 
miRNA Mimics hsa-miR-323a-3p and the Negative Control #1 (all from Life 
Technologies) were used for the transfection. The transfected T cells were 
cultured at the starting concentration of 10
6
 cells/ml in TexMACS Medium 
(Miltenyi Biotec) for 72 hours at 37°C with an additional stimulation of PMA 
(25 ng/ml) and Ionomycin (1 ug/ml) during the last 6 hours. 
Isolation of total RNA, cDNA synthesis and reverse transcription 
quantitative PCR (RT-qPCR)   
Total RNA was extracted using miRNAeasy Mini Kit according to the 
manufacturers’ instructions (Qiagen Valencia, CA, USA). For mRNA 
expression analysis, cDNA was synthesized from 100-900 ng of total RNA with 
oligo-dT, RiboLock RNase Inhibitor, RevertAid First Strand cDNA Synthesis 




Scientific, Waltham, MA, USA). RNA concentration and quality were assessed 
with the NanoDrop ND-1000. 5xHOT FIREPol EvaGreen qPCR Supermix 
(Solis BioDyne, Tartu, Estonia) and ABI Prism 7900 or Via7 were used for 
qPCR. The relative gene expression levels were normalized to the level of 
human EEF1A1 and calculated using the comparative Ct (∆∆Ct) method (Life 
Technologies, Carlsbad, CA, USA). SMAD2 for: GAA AGG GTG GGG AGC 
AGA AT, SMAD2 rev: TCC AAC CAC TGT AGA GGT CCA, SMAD3 for: 
CCT AGG GCT GCT CTC CAA TG, SMAD3 rev GAC CTC CCC TCC GAT 
GTA GT, SMAD5 for: GTT TGC TCA GCT TCT GGC TC, SMAD5 rev: CGG 
TGA TAT TCT GCT CCC CAA, CDKN1B for: TCC GGC TAA CTC TGA 
GGA CA and CDKN1B rev: GGT TGC AGG TCG CTT CCT TA were 
designed with the assistance of Primer 3 and were ordered from TAG 
Copenhagen (Copenhagen, Denmark). qPCR primers for human CCL5, IRAK1 
and EEF1A are described before [301]. miRNA qPCR was carried out using 
TaqMan microRNA Assays (Life Technologies) and using 5× HOT FIREPol® 
Probe qPCR Mix Plus (ROX) (Solis BioDyne). miRNA RT-qPCR results were 
normalized to miR-19b. Relative expression is shown compared to the mean of 
control experiments or the control group (=1) both in mRNA and miRNA RT-
qPCR. 
Enzyme-linked immunosorbent assay (ELISA) 
IL-17A and IL-22 amounts in the supernatants of T cells were measured 
using READY- SET- GO! Human Interleukin-17A (eBioscience, Aachen, 
Germany) and Human IL-22 DuoSet (R&D Systems, Minneapolis, MN, USA) 
ELISA kits according to manufacturers’ protocols. Briefly, 96-well half-area 
microplate wells (Greiner Bio-One) were covered with 30 µl of purified  
anti-IL-17A (dilution 1:250 in coating buffer) or anti-IL-22 (2 µg/ml in PBS) 
antibodies and incubated overnight at 4°C (IL-17A) or at the room temperature 




(IL-17A) or 2% BSA (IL22) for 1 hour, washed again, incubated with 30 µl of T 
cell culture supernatants overnight at +4°C and further manipulated as described 
in manufacturers’ protocols.  
 
Statistics 
Statistical analysis was performed using unpaired Students t-test. The 
results were considered significant at P<0.05. 





Differential expression of miRNAs in IL-22-positive T cells 









) T cell populations were 
sorted from PBMCs of healthy donors using an intracellular staining approach 
(Fig. S1), and miRNA expression profile of both cell populations was 
determined using human TaqMan MicroRNA microfluidic cards.  A total of 18 
miRNAs were found to be differentially expressed with more than a 2-fold 








 T cells (Fig. 1A). In this 
set of miRNAs, miR-323-3p, miR-886-5p, and miR-886-3p were significantly 





 cells (Fig. 1B). Additional analysis of IL-22-
single positive, IL-17-single positive, IL-17- and IL-22-double positive, and IL-





















) (Fig. S1B) confirmed that 
in IL-17- and IL-22-producing T cells, the expression of miR-323-3p and miR-
886-5p was increased in comparison to the non-producing cells (Fig. 1C).  
miRNAs differentially expressed in IL-22-positive T cells may 
influence T cell functions 
To analyze whether miRNAs differentially expressed in IL-22-positive T 
cells could potentially influence the differentiation and functions of T cells, we 
performed pathway analysis with g:Profiler for the best scored and conserved 
miRNA targets defined by Targetscan 6.2 and expressed in the CD4(+) T cells. 
The pathway analysis revealed a significant overlap between miR-323-p,  
miR-26a, miR-874, miR-93 and 146a targets with numerous GO groups and 
KEGG pathways that impact T cell development, immune responses to 
pathogens and cytokines, tissue regeneration and apoptosis (Table 1). miR-886-




recently shown to represent a 139 nt long noncoding RNA nc886 that functions 
as a repressor of interferon-induced, double-stranded RNA-activated protein 
kinase [302].  
miR-323-3p targets genes from TGF-β signaling pathway and inhibits 
the production of IL-22 in T cells  
The integrated pathway and target analysis suggested that miR-323-3p 
could modulate the expression of the genes regulating cellular responses to 
TGF-β (Table 1), a cytokine that plays a role in Th17 cell differentiation and in 
the regulation of IL-22 production by Th17 cells [284]. We therefore analyzed 
the capacity of miR-323-3p to influence putative direct targets from the TGF-β 
signaling pathway. In particular, we cloned fragments of 3’ untranslated regions 
(3’ UTRs) of SMAD 2 (mothers against decapentaplegic homologue 2), 
SMAD3, SMAD5 and cyclin-dependent kinase inhibitor 1B (CDKN1B, also 
known as p27) containing predicted miR-323-3p binding sites (Table 2) into the 
luciferase reporter vector. The cloned reporter plasmids were transfected 
together with the miR-323-3p or the control mimic into human embryonic 
kidney 293 (HEK293) cells followed by the luciferase assay. miR-323-3p 
suppressed the luciferase activity of the reporters containing 3’ UTR regions of 
SMAD3, SMAD5 and a conserved binding site of CDKN1B (Fig. 2A).  
To clarify whether miR-323-3p has capacity to influence the expression of these 
direct targets in T cells, we next transfected bead-purified CD3 positive T cells 
together with miR-323-3p mimic, negative control mimic or precursor for  
miR-146a, which we also observed to be differentially expressed in IL-22-
positive T cells (Fig. 1B). As demonstrated in Fig. 2B, miR-323-3p suppressed 
SMAD2, SMAD3 and CDKN1B and moderately influenced SMAD5 mRNA 
expression in cultured CD3(+) T cells. miR-146a, which was used as a positive 
control inhibited previously described direct targets IL-1 receptor–associated 




miR-323-3p mimic suppressed the expression of IL-22 mRNA (Fig. 2D) and the 
secretion of IL-22 protein (Fig. 2E), while the IL-17A levels were not 
significantly changed. Transfection of miR-146a precursor did not significantly 
influence IL-17A and IL-22 mRNA and protein levels (Fig. 2D-E). These results 
together demonstrate that miR-323-3p targets multiple factors from the TGF-β 
pathway and strongly inhibits IL-22 production in T cells.  
The expression of miR-323-3p is increased in PBMCs from patients 
with asthma  
To study whether miR-323-p expression is altered and can potentially 
impact immune responses in allergic diseases, we next analyzed the expression 
of miR-323-3p in PBMCs from patients with asthma and AD and from healthy 
controls. We observed significantly increased expression of miR-323-3p in 
PBMCs from patients with asthma compared to control individuals (Fig. 3). The 
level of miR-323-3p in PBMCs from AD patients was comparable with the 



















The functions of miRNAs in the regulation of immune responses in 
allergic diseases are largely unexplored. In this study, we demonstrated for the 
first time that the IL-22-producing T cells have a distinct miRNA expression 
pattern. We show the increased expression of miR-323-3p in IL-22/IL-17-
producing T cells and in the PBMCs from patients with asthma. In addition, we 
demonstrate that miR-323-3p targets multiple genes from the TGF-β signaling 
pathway and inhibits IL-22 production by T cells. These results together suggest 
that miR-323-3p might impact T cell responses in asthma.  
Previously, several miRNAs have been shown to influence the 
development, phenotypic stability and functions of T cells.  For example,  
miR-10a limits Th17 cell differentiation and keeps phenotypic stability of 
inducible Treg cells via targeting the transcriptional repressor Bcl-6 in mice 
[293]. As another example, miR‑ 326 targets Ets1, which is a negative regulator 
of Th17 cell differentiation, leading to increased Th17 cell differentiation in 
vitro [278]. A recent study on miR-155-/- and miR-146a-/- T cells identified that 
T cell-intrinsic miR-155 is required for type-2 immunity, whereas T-cell-
intrinsic miR-146a is needed to prevent Th1/Th17 skewing [304]. Similarly, the 
pathway analysis we performed suggested that miRNAs differentially expressed 
in IL-22-positive cells might impact the development, proliferation and immune 
responses of T cells. Two microRNAs, miR-886-5p and miR-886-3p were 
excluded from the pathway analysis, as the corresponding PCR probes were 
recently shown to recognize a 139 nt long noncoding RNA nc886 that functions 
as a repressor of interferon-induced, double-stranded RNA-activated protein 
kinase [302]. However, this finding is interesting as the increased expression of 
nc886 in IL-22-positive cell subset might refer to the reduced interferon 




Next, we focused our functional experiments on miR-323-3p as pathway 
analysis suggested that it may target genes involved in the regulation of the 
TGF-β pathway. We determined SMAD3, SMAD5 and CDKN1B as the direct 
miR-323-3p targets, of which SMAD3 and CDKN1B were also inhibited by the 
transfection of miR-323-3p mimics into T cells. SMAD3 and SMAD5 are 
regulatory SMADs that upon activation by phosphorylation form homo-
oligomeric and hetero-oligomeric complexes with the co-mediator SMAD and 
translocate to the nucleus, where they function together with transcriptional 
activators and repressors in the modulation of gene expression [305] (Fig. S2). 
CDKN1B (also known as p27) controls the cell cycle progression at G1 [306]. 
This together suggests that miR-323-3p might impact the progression of the cell 
cycle and the expression of cytokines. Indeed, we observed a strong 
downregulation of IL-22 mRNA and protein levels when we transfected  
miR-323-3p into T cells.  TGF-β is an important cytokine needed for Th17 cell 
differentiation, where it has been shown to suppress the production of IL-22 (1). 
Thus, although miR-323-3p targets several genes from the TGF-β pathway, it 
cooperates with TGF-β in the suppression of IL-22 production. In addition to 
miR-323-3p direct targets we characterized in this study, there also exist most 
likely additional miR-323-3p targets that influence the production of  
IL-22.  
IL-22-producing cells consist of a mixture of IL-22-single positive and  
IL-22/IL-17 co-producing cells. We observed slightly higher expression of  
miR-323-3p in IL-17-positive and IL-17/IL-22 double-positive cells, which may 
suggest that higher miR-323-3p level inhibits the production of IL-22, and thus 
shift them towards Th17 cells.  
miR-323-3p is encoded by 14q32 cluster of miRNAs in humans containing 
46 putative miRNA genes that are imprinted and expressed on the maternally 
inherited chromosome [307].  miRNAs from the 14q32 cluster are deregulated 




aggressive variants of adenocarcinoma of the lung [309]. An increased 
expression of miR-323-3p has been demonstrated in synovial fibroblasts in 
rheumatoid arthritis [310]. In another study, an overexpression of miR-323-3p 
has been shown to enhance activation of the Wnt pathway and to decrease the 
levels of its predicted target β-transducin repeat containing an inhibitor of beta-
catenin [311]. The precise function of miR-323-3p and the whole cluster in 
immune system remains to be elucidated.  
A growing body of data suggests that both Th17 cells and Th22 cells have 
important roles in allergic diseases. The Th17 cells have been demonstrated to 
be central in neutrophilic airway inflammation [290, 291]. IL-22 was shown to 
suppress recruitment of eosinophils and goblet cell hyperplasia in an antigen-
induced airway inflammation in mice [289]. The levels of both IL-22 and IL-17 
in serum of patients with asthma have been shown to be increased [312, 313].  
In correlation with this, we currently observed the increased expression of  
miR-323-3p in PBMCs from patients with asthma. Further studies are needed to 
determine the role of miR-323-3p in IL-22/IL-17-producing T cells and asthma. 
In conclusion, we demonstrated the increased expression of miR-323-3p 
in IL-22/IL-17-producing T cells of healthy individuals and in the PBMCs from 
patients with asthma, as well as the capacity of miR-323-3p to suppress IL-22 in 
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Figure 1 Human IL-22-positive T cells have distinct miRNA expression profile (A). Heatmap 
of the differentially expressed miRNAs in IL-22-positive T cells. Log2 expression values for 
each of the miRNAs are mean-centered across all samples for each gene separately. Color 
scale from blue (lower) to red (higher) represents deviation from the mean (black). (B)  
The relative levels of miRNAs with significantly different expression in IL-22-positive T 
cells. (C) Relative expression of the indicated miRNAs in IL-17-single positive, IL-22-single 
positive, IL-17- and IL-22-double positive, and IL-17- and IL-22-double negative cell 
populations. (B, C) Data represent the mean ± SEM of three independent healthy donors. 
Student’s t-test, *P < 0.05, **P < 0.05 
Figure 2 miR-323-3p inhibits genes from the TGF-β pathway and IL-22 production in human 
T cells. (A) The relative firefly luciferase (LUC) activity is compared to the control 
transfection (cont,=1), (n=6). (B-E) Purified CD3+ T cells were cultured 24h, transfected with 
pre-miR-146a (miR-146a), miR-323-3p or the control (cont) mimics, further cultured for 72h 
with an additional PMA/Ionomycin stimulation during last 6h. (B-D) The relative mRNA 
expression is shown compared to the average value in control transfected cells (cont,=1; n=7; 
cells were from 2 different healthy donors). (E) Quantification of IL-22 and IL-17 in the cell 
supernatants (n=4, cells from one representative healthy donor). (A-E) Data represent mean ± 
SEM, Student’s t-test, *P < 0.05, **P < 0.05. 
Figure 3 miR-323-3p is increased in PBMCs from patients with asthma. The relative 
expression of the miR-323-3p and miR-146a in PBMCs from patients with bronchial asthma 
(BA) and atopic dermatitis (AD) is shown in comparison with the control group. Student’s  






















































Table 1. miRNAs differentially expressed in IL-22-positive T cells potentially 




 Nr of 
targets 
ID Functional group an nr genes in the 
group 





1.04e-02 282 CORUM:3961 SMAD3-cSKI-SIN3A-HDAC1 
complex 
4 SIN3A,SKI,SMAD3 
























6.79e-06 392 GO:0002252 immune effector process 761 ADAR,AP1S1,BCL2,BTN3A2,BTN3A3,CD247,CD59,CFL1,
CLEC7A,CRK,CYFIP2,IRF5,ITPR2,MYO1C,NBN,POU2F2,R
AB27A,SLC11A1,STAT2,TARBP2,TRIM25,VAV3 
3.82e-04 392 GO:0042110 T cell activation 453 AP3D1,BCL2,BTLA,BTN3A1,CD247,CD276,CD5,CD59,CL
EC7A,MAP3K14,MYH9,PTPN22,RAB27A,SLC11A1,SMAD
3 





2.10e-05 392 KEGG:04010 MAPK signaling pathway 289 ARRB1,CDC25B,CRK,DUSP22,IKBKB,MAP2K4,MAPK8IP3
,NFATC1,PLA2G4C,PPM1A,STMN1,TAOK2 
1.11e-03 392 KEGG:04668 TNF signaling pathway 129 CREB1,CREB3L2,IKBKB,MAP2K4,RIPK1,TNFRSF1B,TRAF1 







3.91e-02 317 GO:0045321 leukocyte activation 719 BCL2,CBLB,CHD7,PAG1,PDPK1,PRDM1,PRKCD,PTPRE,R
ORA,ZFP36L1,TNFSF11,TNFSF4,TXK,YWHAZ 
2.32e-03 317 GO:0097191 extrinsic apoptotic 
signaling pathway 
153 BCL2,CYLD,DDX3X,ITGA6,MADD,MCL1,PDPK1,PHIP 
7.09e-03 317 KEGG:04010 MAPK signaling pathway 289 DUSP5,MAP2K1,MAP3K3,MAP4K4,MKNK2,NLK,RPS6KA
3,TAOK1 



















5.91e-03 231 GO:0000165 MAPK cascade 599 ATF2,PRKCD,ADAM9,VANGL2,PLCB1,TRIB2,TAB3,LPAR3
,DAB2,CTGF,FGF14,FGF21 
1.29e-02 231 KEGG:04310 Wnt signaling pathway 150 VANGL2,PLCB1,FRAT2,SMAD4,TCF7L2 
 
A 
Significance designates the P value from Fisher exact test showing the significance of the 
















310-317 nt of SMAD2 3' UTR 
 
 
5'  ...UAGUUAUGUGUACAGGUAAUGUA... 
                      |||||||  
3'       UCUCCAGCUGGCACAUUACAC  
Conserved, 
-0.2 
3980-3987 nt of SMAD3 3' UTR 
 
 
5'    ...UUUUUUAAUGCAGAAGUAAUGUA... 
                        |||||||  
3'         UCUCCAGCUGGCACAUUACAC  
Conserved, 
-0.17 




                     |||||||  
3'      UCUCCAGCUGGCACAUUACAC  
Conserved, 
-0.07 




                     |||||||  
3'      UCUCCAGCUGGCACAUUACAC  
Conserved 
-0.24 
439-445 nt of CDKN1B 3' UTR 
 
 
5'  ...GUUUUCUUUAAAGAUGUAAUGUC... 
                      |||||||  




APositions are shown from the first nt of the corresponding human gene 3’UTR 
B
Conserved = conserved across most of the mammals, but usually not beyond placental 
C
The context+ score for a specific site is the sum of the contribution of six features, including 











Supporting figure legends 
Figure S1 Sorting strategy for the IL-22- and IL-17-positive T cells. Gating strategy for 
sorting of IL-22-producing T cells (A) and IL-17- and IL-22-single or double-producing  
T cell-subsets (B). Based on the forward scatter (FSC) and side scatter (SSC) characteristics 
of the cells, the lymphocyte population was included in the analysis. After doublet cells 
exclusion using height (FSC-H, SSC-H) and width (FSC-W, SSC-W) of the peak, viable 
CD3+ T cells producing IL-22 and not producing IL-22 were sorted (A). The very same 


























) T cells. Quadrant gates were applied based on the isotype control (IC) 
staining.  
 
Figure S2 Proposed model of miR-323-3p action in the IL-17/IL-22-positive T cell-subset. 
The presence of TGF-β is needed for the development of functional Th17 cells, but at the 
same time it generally counteracts the production of IL-22. The binding of TGF-β induces the 
assembly, auto-phosphorylation and activation of the type I and type II TGF-β receptors, 
followed by phosphorylation of R-SMAD (receptor-regulated SMAD, mothers against 
decapentaplegic Homologue)) proteins [305]. SMAD3 is a R-SMAD protein from the 
canonical TGF-β pathway. SMAD5 is a R-SMAD protein that participates in signaling 
mediated by the bone morphogenic protein (BMP) (not shown in the figure) [305] and 
possibly by TGF-β [314]. Phosphorylated R-SMADs form homo-oligomeric and hetero-
oligomeric complexes with the co-mediator SMAD (Co-SMAD). These complexes are 
translocated into the nucleus, where they associate with transcriptional activators or repressors 
(TA/R) to regulate the transcriptional activity of numerous genes [305].  miR-323-3p targets 
the TGF-β pathway through direct targeting of SMAD3, SMAD5, and cyclin-dependent 
kinase inhibitor 1B (CDKN1B, also known as p27) and thereby also modulates the expression 
of other regulators of the cell cycle, including CDKN2B (also known as p15) and cell 


















6.2 Transcriptomic characterization of human  
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CD4+ T cells differentiate into effector T cells upon antigen recognition 
during immune synapse formation and delivery of three signals by antigen-
presenting cells. The main subsets of effector T helper cells are: Th1, Th2, Th9, 
Th17 and Th22 cells. Among all T helper cell subsets, IL-22-producing T cells 
have been characterized to a lesser extent as compared to other subsets.  
The present study for the first time shows next generation RNA sequencing 
analysis of human IL-22-producing T cells and proposes the genes that are 
describing in detail human IL-22-producing T cells. However, further 
investigation of the biological function of these molecules in IL-22 secreting T 
cells is required. Additionally, there is certainly a need to distinguish between 
IL-22-producing Th17 cells and IL-22-producing Th22 cells and better 
characterize these pure human Th22 cells. 
Key Words 
Next generation sequencing, Th22, Th17, IL-17A, IL-22, cytokines, 













To the Editor: 
T cells mediate adaptive immune responses via the activation of other 
immune cells and the regulation of tissue cells to eliminate bacterial, fungal and 
viral pathogens and maintain homeostasis. Based on cytokine production 
patterns, T helper cells are classically subdivided into Th1, Th2 and T regulatory 
cells [315]. Recently, new subsets of T helper cells, including Th9, Th17 and 
Th22 cells have been described [89, 147]. The main cytokine produced by Th17 
and Th22 cells is interleukin-22 (IL-22) [316]. Because of the preferential 
expression of IL-22R1 on cells of epithelial origin, IL-22 is a unique cytokine 
produced by immune cells and acts only on tissue cells [127]. The effects of IL-
22 on tissue cells can be grouped into five main categories. First of all, IL-22 
influences terminal differentiation of keratinocytes [171]. Secondly, IL-22 via 
the induction of antibacterial protein production by epithelial cells increases the 
innate immune defense mechanisms against microbes [169]. Additionally, it 
enhances the production of chemokines by epithelial cells and the migratory 
ability of epithelial cells [169, 172]. Finally, by the upregulation of STAT3, IL-
20 and IL-22 show a self-perpetuating action on epithelial cells [317, 318]. On 
the contrary, when it is uncontrolled, IL-22 may lead to inflammation that can 
be seen in psoriasis [317], atopic dermatitis [177] or rheumatoid arthritis [197]. 
As compared to other cytokine-producing cells, IL-22-producing T cells are 
poorly characterized so far. One of the possible reasons may be due to the lack 
of a key transcription factor responsible for induction of IL-22 production.  
Because of unique role of IL-22 in the regulation of epithelial cells, the 
characterization of IL-22-producing T cells was performed in human palatine 
tonsils, where T cells are in close proximity to epithelial cells. In the present 
study, viable human IL-22-producing T cells from palatine tonsils have been 
isolated with the use of our newly generated IL-22-secretion assay and next 





First of all, the general characterization of tonsillar T cells in terms of the 
production of the main Th1/Th2/Th17/Th22-derived cytokines (IL-22, IL-17A,  
IL-10, IL-4, IL-13 and IFN-γ) was assessed in healthy as well in allergic donors 
by intracellular cytokine staining after PMA and ionomycin stimulation  
(Fig. 1 A-C) (Suppl. Figure 1A). There was no difference in cytokine production 
including IL-22 between healthy and allergic donors (Figure 1A). In both 

































 cells in both groups (Suppl. Figure 1B). Next, the co-expression 
analysis of IL-17, IL-10, IL-4, IL-13 and IFN-γ by IL-22-producing CD4+ T 
cells revealed that most of the IL-22-producing cells either co-express IL-4 only 
or co-express IL-17 only or produce IL-22 alone (Figure 1B). Interestingly, 
when a similar analysis was performed for IL-17-producing, IL-4-producing, 
IFN-γ-producing and IL-10-producing T cells, the percentages of single IL-17-
positive, single IL-10-positive, single IL-4-positive or single IFN-γ-positive 
cells were statistically higher when compared to IL-22-single producing T cells 
(Figure 1C, Suppl. Figure 1C). The results mentioned above support the 
common understanding that IL-22 is a bifunctional cytokine, which may play 
both protective and pro-inflammatory roles on epithelial cells depending on 
cytokine environment.  
Furthermore, we investigated which stimuli were optimal for the 
induction of IL-22 production by T cells. Firstly, tonsil mononuclear cells 
(TMC’s) have been stimulated with all Toll-like receptor ligands and Poly (I:C), 
a TLR3 ligand was found to induce IL-22 production from TMC`s (Figure 1D). 
To clarify which cells are responsible for IL-22 production, T cells have been 
isolated from TMC`s and stimulated with this TLR3 ligand in the presence of 




cells indicated that the stimulation with TLR3L, IL-7 and IL-23 is optimal for 
IL-22 induction from T cells.  
To date, the only method to analyze IL-22-producing cells is cytokine 
intracellular staining in which the permeabilization - fixation protocol leads to 
cell death, therefore these cells are not suitable for culture and detailed analysis. 
To overcome this problem, an in-house IL-22-secretion assay has been 
developed (Suppl. Figure 1A). 
Cells stimulated with the combination of TLR3 ligand, IL-7 and IL-23 
have been sorted with this IL-22 secretion assay and mRNA expression for IL-
17, IL-22 and IFN-γ was measured. The analysis of mRNA for cytokines shown 
in figure 1G suggest that it is possible to detect and successfully sort the IL-22-
producing T cells that are characterized by the high expression of IL-22. 
Furthermore, sorted IL-22-positive and IL-22-negative T cells have been 
cultured in the presence of common gamma chain receptor cytokines (Suppl. 
Figure 2B, Suppl. Figure 2C). Two days after sorting, and during the long-term 
culture, sorted cells retain their initial cytokine profile suggesting that the IL-22-
secretion assay is a reliable tool for the isolation of IL-22-producing T cells.  
Next generation RNA sequencing analysis of IL-22-producing and IL-22-
non-producing T cells has been carried out. Differential gene expression 
analysis revealed that 57820 genes are differentially expressed in IL-22-
producing T cells as compared to IL-22-negative T cells. To narrow down the 
number of genes: genes only expressed in 3 out of 4 donors in either IL-22-
positive or IL-22-negative T cells with the intensity values above 0, with a log2 
value ratio ≥ 1 or ≤ -1 and differently expressed with the p-value below 0.01 has 
been included in the analysis. A list of 601 genes fulfilling the above mentioned 
criteria has been analyzed with the help of Metacore – data mining and pathway 
analysis software. 13 genes recognized as coding receptor ligands, 13 genes as 




identified within the list as differentially expressed between IL-22-positive and 
IL-22-negative T cells (Figure 2, Suppl. Figure 3). 
Signature genes characterizing IL-22-producing T cells may be 
subdivided into 3 main groups: cytokines and chemokines, G protein-coupled 
receptors (GPCRs) and transcription factors (TFs). Among the cytokines, IL-22-
producing T cells express higher levels of IL-22, IL-17A, IL-17F, IL-1A, IL-9, 
IL-21, IL-26 and CCL1, CCL2, CCL20 (Figure 2A). As IL-17A and IL-17F 
production by IL-22-positive T cells have been already described, other 
molecules are reported for the first time to be co-expressed together with IL-22. 
Interestingly, IL-9, which is secreted by IL-22-producing cells acts on variety of 
cells including mast cells, T regulatory cells, Th17 cells and antigen presenting 
cells [319]. Furthermore, IL-26, a member of the IL-10 cytokine family acts 
mainly on monocytes [320]. Interestingly, IL-26 was found to kill extracellular 
bacteria via membrane-pore formation. IL-26 forms complexes with prokaryotic 
and eukaryotic DNA that trigger the production of type I interferon by pDCs 
[321]. IL-21 induces IL-22 production from T cells and may serve as a positive 
feedback loop [322]. Additionally, CCL1 has been indicated to be involved in 
Th2 and Treg cell trafficking, CCL2 has been reported in inflammatory 
monocyte trafficking and CCL20 in Th17 responses [323]. Collectively, this 
data suggests that IL-22-producing T cells may influence the tissue responses 
and at the same time through the production of other cytokines and chemokines 
may influence immune cells and exhibit a broader effect on the immune system. 
As IL-22 is known to be bi-functional, depending on the cytokine milieu [324], 
it remains unclear what would be the functional effect of IL-22 on the immune 
cells in the context of the above mentioned co-produced cytokines. At the same 
time, IL-22-producing T cells differentially express CCR5, CXCR4 and CXCR6 
that may be used as surface markers of IL-22-producing cells (Figure 2B). 
Interestingly, CCR5 is described as an inflammatory chemokine receptor [323]. 




of CCR5 on Treg cells, which is critical for its migration to tissues infected with 
fungal pathogens [325] and Leishmania major [326]. Additionally, during graft-
versus-host disease, CCR5 mediates the accumulation of Treg cells in the graft-
versus-host disease target organs [327]. In the islet allograft transplant model, 
Treg migration from the blood to inflamed transplant tissue requires CCR5 
expression [328]. A similar role in relation to migration of cells to tissue was 
found for CXCR6 which promotes NKT cells residence in peripheral tissues like 
liver and lung [329]. In contrast, another chemokine receptor expressed by IL-
22-positive T cells - CXCR4, mediates CCR7-independent entry to the lymph 
nodes [330]. It is possible that chemokine receptors expressed differentially on 
IL-22-positive cells may guide the migration of these cells to inflamed tissues 
where they may influence tissue epithelial cells via the production of IL-22. 
Finally, among potential transcription factors upregulated in IL-22-
producing T cells, - PPARG and among transcription factor downregulated in 
IL-22-producing T cells - FOS, bind directly to the IL22 promotor and may 
influence the IL-22-production directly [SABiosciences` proprietary database] 
(Figure 2C). The role of other transcription factors upregulated (MAF, EPAS1, 
MSC, CITED) and downreagulated (EGR1, EGR4, ZXDA) in IL-22-positive T 
cells has to be investigated in more details. 
In summary, the present study, for the first time shows the next generation 
RNA sequencing analysis of human IL-22-producing T cells and proposes the 
genes that can characterize human IL-22-producing T cells in detail. 
Furthermore, the investigation of biological function of these molecules in IL-
22-secreting T cells is required. Additionally, there is a need to distinguish 
between IL-22-producing Th17 cells and IL-22-producing Th22 cells to better 









Figure 1. Characterization of human IL-22-producing T cells. 
Tonsil mononuclear cells from healthy and allergic individuals were stained intracellular for 
IL-22, IL-17A, IL-4, IL-13, IL-10 and IFN-γ. The expression of cytokines was analyzed in 
viable CD3+CD4+ T cells (A). Co-expression of IL-17A, IL-4, IL-13, IL-10 and  
IFN-γ by CD3+CD4+IL-22-producing T cells was evaluated (n=7) (B). IL-17A, IL-4, IL-13, 
IL-10 and IFN-γ-producing T cells and cells expressing a single cytokine of interest that do 
not express other cytokines has been shown (C). To investigate the optimal culture conditions 
to induce IL-22 production, TMCs from healthy donors were stimulated with a combination 
of TLR3 ligand (Poly I:C), IL-7 and IL-23 and mRNA expression of IL-22 has been analyzed 
(n=3) (D). IL-22 protein levels in the culture supernatants of TMCs (E) and T cells isolated 
from TMC`s (F) stimulated in the presence of TLR3 ligand IL-7 and IL-23 was measured 
(n=4). (G) Relative mRNA expression of IL-22, IL-17 and IFN-γ by IL-22-positive and IL-
22-negative T cells sorted with IL-22-secretion assay is shown (n=3).  
(C) One-way Anova test with multiple comparisons was calculated ( *** p<0.0005). 
(F) Mann Whitney test was applied (* p<0.05). 
 
Figure 2. Next generation sequencing characterization of human IL-22-producing T 
cells.  
Reads per kilo base per million (RPKM) values of differentially expressed genes between  
IL-22-positive over IL-22-negative T cells has been plotted for cytokines and chemokines 











































Online Repository Figure Legends: 
Supplementary figure 1. Cytokines intracellular staining characterization of human 
tonsillar T cell. 
For the gating strategy for intracellular staining of cytokines produced by T cells in tonsil 
mononuclear cells, firstly, cell doublets were discriminated. Later only viable, CD3+CD4+ 
positive T cells were included and every cytokine was plotted against the CD4 marker to 
show the percentage of cytokine-producing CD3+CD4+ T cells (A). The comparison of 
cytokine-producing CD3+CD4+ cells in healthy and allergic donors was analyzed (B). Co-
production of other cytokines by cytokine-producing T cells were analyzed using the TREE 
function of KALUZA software which allows to calculate all possible combinations of 
coproduction of 5 cytokines by specific cytokine-producing cells. In this analysis, 100% of 
cells are considered as all cells that are able to produce specific cytokine (C). One-way Anova 
test with multiple comparisons was used (* p<0.05,** p<0.005,*** p<0.0005). 
Supplementary figure 2. T cells sorting with IL-22-secretion assay. 
Gating strategy for sorting of IL-22-positive and IL-22-negative CD3+CD4+ T cells from 
tonsils (A). Gates defining the positive population were set up based on a control that did not 
contain anti-IL-22-catch reagent (A). In both sorted populations mRNA expression of 
common gamma chain receptor family receptors has been analyzed (B) and sorted IL-22-
positive and IL-22-negative cells have been cultured in the presence of IL-2 and the profile of 
cytokine production was assessed on day 2 and day 7 after second re-stimulation with anti-
CD3, anti-CD2 and anti-CD28 monoclonal antibodies.  
Supplementary figure 3. Validation of anti-IL-22-catch reagent formation. 
IL-22 secretion assay consists of anti-IL-22 catch reagent and anti-IL-22 detection antibody. 
Anti-IL-22 catch reagent is formed by cross linking mouse anti-human CD45 Ab with rat 
anti-human IL-22 Ab. Rat anti-human IL-22 antibody which is the part of anti-IL-22 catch 
reagent was detected with goat-anti rat AF488 Ab to prove that anti-IL-22 catch reagent is 
present on the cells and that catch reagent was formed properly. Different dilutions of catch 
reagent were added to stain 1x10
6
 (A) or 10 x10
6
 (B) cells, ranging from undiluted to 10, 50, 






Supplementary figure 4. Next generation sequencing characterization of human IL-22-
producing T cells. 
Volcano plots for genes upregulated and downregulated in IL-22-positive versus IL-22-
negative sorted T cells (-log10 FDR vs log2 ratio) (A). Heat-map for clustering with GO 
categories for only those genes expressed in at least 75% of samples in either or both samples 
(B). A heat-map normalizing the expression values by pair and sorting samples by patients for 









































The study has been reviewed and approved by the ethics committees of 
the Canton of Graubünden. Non-inflamed tonsils from patients undergoing 
tonsillectomy were obtained from the hospitals of Davos and Chur, Switzerland. 
Purification of cells 
Tonsil mononuclear cells (TMCs) were isolated from freshly removed 
palatine tonsils as previously described [228]. T cells were isolated from TMC`s 
with the use of human CD3 MicroBeads (Milteneyi Biotec, 130-050-101, 
Bergisch Gladbach, Germany) according to manufacturer`s protocol. 
Intracellular cytokine staining 
Thawed tonsil mononuclear cells that rested for 2h at 37
o
C on the Tube 
Rotator (MACSmix Miltenyi Biotec, 130-090-753, Bergisch Gladbach, 
Germany) were stimulated with 25 ng/ml phorbol 12-myristate 13-acetate 
(PMA, Sigma-Aldrich, P-8139, Buchs, Switzerland), 1 µg/ml Ionomycin 
(Sigma-Aldrich, I-0634, Buchs Switzerland) and 1 µg/ml of brefeldin A (Sigma-
Aldrich, B-7651, Buchs, Switzerland) for 4 h in the 24-well plate at a 
concentration of 2x10
6
/ml in cRPMI medium. After stimulation cells were 
washed in PBS and stained for 30 min at 4
o
C with fixable viability dye eFluor 
780 (eBioscience, 65-0865-14, Vienna, Austria) followed by staining with anti-
human CD3 V500  (BD, 561416, Allschwil, Switzerland) and anti-human CD4 
PC5.5 (Beckman Coulter, B16491, Krefeld, Germany). Next, cells were fixed 
and permeabilized with fixation/permeabilization solution for 20 min at 4
o
C (BD 
Cytofix/Cytoperm, Fixation/Permeabilization solution kit, 554714, Allschwil, 
Switzerland). Later, cells were stained with anti-human IL-22 PE (eBioscience, 
12-7229-42, Vienna, Austria), anti-human IL-17A Pacific Blue (Biolegend, 




UK), anti-human IL-13 APC (Biolegend, 501907, London, UK), anti-human IL-
10 PE-CF594 (BD, 562400, Allschwill, Switzerland), anti-human IFN-γ AF700 
(Biolegend, 506516, Londok UK) antibodies diluted in 100 µl of BD 




Flow cytometry analysis 
Cells were acquired with Galios Flow Cytometer (Beckman Coulter, 
Krefeld, Germany) and data was analysed with Kaluza Flow Cytometry 
Analysis Software ((Beckman Coulter, Krefeld, Germany). Co-production of 
cytokines by cytokine-producing T cells was analysed using TREE function of 
KALUZA software, which allows to calculate all possible combinations of 
coproduction of 5 cytokines by specific cytokine-producing cells. In this 
analysis, 100% of cells are considered as all cells, which are able to produce 
specific cytokine 
Development of anti-IL-22 secretion assay 
Purified anti-human CD45 antibody (eBioscience, 7014-0459-M001, 
Vienna, Austria) was conjugated with anti-human/mouse IL-22 purified 
antibody (eBioscience, 7013-7222-U500, Vienna, Austria) with the Pierce 
Controlled Protein-Protein Crosslinking Kit (ThermoFisher Scientific, 23456, 
Zug, Switzerland) according to manufacturer`s protocol. Formed in this way 
antibodies conjugate was used as anti-IL-22 catch reagent. IL-22 bound to the 
anti-IL-22 catch reagent was detected with anti-human IL-22 PE (eBioscience, 
12-7229, Vienna, Austria). For the validation of anti-IL-22 catch reagent 
formation goat anti-rat IgG antibody was used (AF488 conjugated, Invitrogen, 
A11006, Zug, Switzerland) 
Cell culture 
Tonsil mononuclear cells have been cultured in the presence of 20 µg/ml 




in complete cRPMI medium (Gibco Cat. No. 21875-034, Paisley, Scotland) 
supplemented with 1 mM sodium pyruvate, 1% MEM nonessential amino acids 
and vitamins, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, 
50 mM 2-Mercaptoethanol (all from Gibco). T cells isolated from tonsil 
mononuclear cells have been cultured with the mentioned above condition.  
IL-22-positive and IL-22-negative T cells that have been sorted with IL-22-
secretion assay, were expanded in the cRPMI medium in the presence of 1 nM 
IL-2 as a growth factor. After 2 days of culture as well as after 20 days in culture 
(13 days plus 7 days after second re-stimulation) culture supernatants were 
collected and cytokines measured with Bio-Plex Pro Human Th17 Cytokine 
Assay (Bio-Rad, 171AA001M, Cressier, Switzeraland).  
RNA isolation and sequencingAnalysis of RNA-seq data 
Total RNA was isolated using the RNeasy Micro kit (Qiagen, 74034, 
Hombrechtikon, Switzerland) following the manufacturer’s protocol. For 
validation of IL-22 secreiton assay mRNA from IL-22-positive and IL-22-
negative was reverse transcribed with Revert Aid RT Kit (Thermo Scientific, 
K1691, Zug, Switzerland) according to manufacturer`s instructions. Real-time 
quantitative PCR was performed on a 7900HT Fast Real-Time PCR system 
(Thermo Scientific, 4329001, Zug, Switzerland) using Maxima Sybr Green/Rox 
qPCR Master Mix (Thermo Scientific, K0223, Zug, Switzerland) protocol with 
primers, IL-22 reverse primer: 5`TAG CAG CGC TCA CTC ATA CTG 3`, 
forward: 5`TTC ATG CTC GCCT AAG GAG GC 3`, IL-17a reverse primer: 
5`CGG ACT GTG ATG TGC AAC CT3`, forward: 5` TCC TCA TTG CGG 
TGG AGA TT3`.  
Next generation sequencing: RNA quality was assessed by Agilent 2100 
Bioanalyzer, and the RNA integrity number was >7.0. The Library preparation 
for RNA-Seq was performed using the NuGEN Ovation Single Cell RNA-Seq 




were sequenced using HiSeq2500 from Illumina (single end; 1×100 bp). 
Sequence images were transformed with Illumina software BaseCaller to bcl 
files, which were demultiplexed to fastq files with CASAVA v1.8.2 (Illumina). 
Quality check was done via fastqc (v. 0.10.0, Babraham Institute, Cambridge, 
UK). 
Raw sequencing reads were mapped to the Homo sapiens genome 
(GRCh37 build) using RSEM (v1.2.12) [PMID:21816040] implementation of 
Bowtie (v 1.0.0) [PMID:19261174] alignment program with the Ensemble 
annotation (v 75). Gene and isoform level abundances were quantified as RPKM 
values.  Clustering analyses were performed using the ‘ward.D2’ clustering 
algorithm [331] implemented in the ‘hclust’ function of the R stats package. 
Heatmap plots were performed with the function ‘heatmap.2’ implemented in 
the gplots R package [https://cran.rproject.org/web/packages/gplots/index.html]. 
Differential expression analysis between the two conditions was 
performed using edgeR R bioconductor package [PMID:19910308]. Genes 
present in less than 75% in both condition were removed. Q-values were 
calculated using the Benjamini–Hochberg [332]and genes with a q-value < 0.05 
and an absolute value of log 2 (fold change) > 1 were keep for further analyses.  
Gene Ontology (GO) term enrichment analysis was performed using 
GOseq bioconductor package [PMID: 20132535] using the Wallenius 
approximation. In parallel, Pathway analysis was performed with MetaCore 









6.3 A novel, dual cytokine-secretion assay for the 
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 The combination of two cytokine-secretion assays allows the sorting of 
viable  
IL-22-producing cells as well as viable IL-17A-producing cells. 
 For the first time, viable human IL-22-producing Th22 cells that do not 
co-produce IL-17A were purified. 
 The combination of anti-IL-17A and anti-IL-22 secretion assays is 
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Interleukin-22 is produced by certain T helper cells subsets (Th17, Th22) and at 
lower levels by γδT, NKT and innate lymphoid cells. Th22 cells are unique 
immune cells that regulate tissue responses by IL-22 production. The exact 
discrimination between Th17 cells that co-produce IL-22 and single IL-22-
producing Th22 cells has not been possible until the present study. Isolation of 
pure Th22 cells without co-expression of cytokines of other T cell subsets is 
essential to better understand their function in humans. The aim of the present 
study is the isolation and characterization of viable, human IL-22-producing 
CD4+ T cells that do not produce IL-17A. 
Methods  
Isolation of viable Th22 cells was performed with the combination of two 
cytokine secretion assays detecting IL-17A- and IL-22-producing cells in  
a single purification step.  
Results 
The newly developed cytokine secretion assay consists of anti-IL-22 and anti-
IL-17A catch antibodies, which via biotin-streptavidin interaction are bound to 
the biotinylated surface of the target cell, and anti-IL-22 and IL-17A detection 
antibody labelled with a fluorescent dye, which detects cytokines bound to these 
catch antibodies. A unique population of human Th22 cells, which do not 
produce IL-17A, was sorted and cytokine expression pattern was confirmed by 
quantitative PCR analysis and ELISA. The presented technique allows the 







This technique may allow the purification of any single cytokine-producing cell 
subset, and the combination of several different cytokine secretion assays can be  
























Adaptive immune responses mediated by CD4+ T cells are necessary to 
eliminate viral, fungal or bacterial infections. They activate other immune cells 
by releasing T cell cytokines, assist B cells to produce antibodies, and regulate 
the immune system and tissue cells. CD4+ T cells can be characterized 
according to their cytokine production patterns [333]. New subsets of T helper 
cells were described during the last decade, including Th17 and Th22 cells [138, 
146, 147]. There is still an ongoing debate and no clear distinction between 
Th17 and Th22 cells in humans, because the main cytokine of Th22 cells, IL-22, 
can be also produced by Th17 cells. Most of the confusion in the assigning  
IL-22 as Th17 rather than Th22 cytokine comes from discrepancy between 
mouse and human data. Among all mouse T helper subsets, Th17 cells are the 
major source of IL-22 and IL-22 is named as Th17 cytokine [141-143].  
In contrast, IL-22 production by human cells does not correlate with either 
RORγt or IL-17A [139] and only 10-18% of IL-22-producing T cells in blood 
co-express IL-17A [138].  
IL-22 together with IL-10, IL-19, IL-20, IL-24, IL-26, IL-28A, IL-28B,  
IL-29 is a member of the IL-10 cytokine family [121]. Cells of both, the innate 
and adaptive arms of the immune system, including αβ and γδ T cells, NKT and 
innate lymphoid cells, can produce IL-22. IL-22 was initially described as a 
cytokine produced by Th1 cells [126]. Although, IL-22 was co-produced by 
Th17 cells, it was later demonstrated that a fraction of human IL-22-producing T 
cells do not co-produce IL-17A, IL-4 or IFN-γ, which led to definition of new 
subset of T helper cells, named Th22 cells [138, 146, 147]. The main reason 
why IL-22 is considered a Th17 cytokine is that in mouse models, Th17 cells are 
the major source of IL-22. To date, characterization of human Th22 cells is 
mainly performed with in vitro manipulated T cell clones or cells expressing  












[138, 146]. However, these cells have not been shown to be proven 
representatives of Th22 cells as CCR10+CCR6+CCR4+ skin homing T cells are 
only enriched for T cells that produce IL-22 and most of them still co-produce 
other cytokines. 
IL-22 binds to the IL-22 receptor (IL-22R), which consists of two subunits: 
IL-10R2 and IL-22R1 [119, 120]. IL-22 is a unique cytokine that is produced by 
immune cells and acts solely on non-immune tissue cells [334]. In general, the 
effects of IL-22 on epithelial cells in gut, skin and lungs can be divided into five 
main categories. Interleukin-22: 1) increases innate defense mechanisms against 
microbes via the induction of antibacterial protein production by epithelial cells 
[318, 335-337], 2) influences terminal differentiation of keratinocytes, 3) 
enhances the production of chemokines by epithelial cells [337], 4) and 
enhances migratory ability of epithelial cells [318, 338], and 5) shows a self-
perpetuating action by upreguation of STAT3 and IL-20 [317, 339]. 
There is no consensus on the functions of single- and IL-17A/IL-22-co-
producing cells so far. Uncontrolled IL-22-production can lead to pathogenesis, 
as demonstrated in psoriasis [171, 317], atopic dermatitis [340], rheumatoid 
arthritis [341], and Toxoplasma gondii infection [342]. One of the factors that 
may determinate the pro-inflammatory versus protective outcome of IL-22 
action is the presence of IL-17A. For example, in the bleomycin induced acute 
airway inflammation model in mice, where Th17 cells co-produce IL-17A and 
IL-22, the disease is ameliorated in anti-IL-22 treated WT mice or IL-22-/- mice. 
Additionally, IL17-A-/- knockout mice are protected from airway inflammation, 
suggesting that IL-17A synergizes with IL-22 in this model [324]. These studies 
explain why it is important to understand the mechanisms of regulation of the 
production of both cytokines and the effects of single cytokine-producing versus 
IL-17A- and IL-22-co-producing cells. The present study describes combined 
IL-17A/IL-22 secretion assays allowing to purify and culture single IL-22-




producing Th17/Th22 cells. This method may improve our understanding of the 
physiological and pathogenic functions of cells co-producing cytokines or 
producing them individually in various diseases, and can be used to identify 































CD4+ T cell isolation 
Peripheral blood mononuclear cells (PBMC`s) were isolated from buffy coats 
and whole blood using density gradient centrifugation (Biochrom, L6155, 
Berlin, Germany). CD4+ T cells were isolated using an anti-human CD4+ T 
cells isolation kit (Miltenyi Biotec, 130-096-533, Bergisch Gladbach, Germany) 
and cultured overnight at 37
o
C for further experiments in cRPMI 1640 medium 
(Gibco Cat. No. 21875-034, Paisley, Scotland) supplemented with 1 mM sodium 
pyruvate, 1% MEM nonessential amino acids and vitamins, 2 mM L-glutamine, 
100 U/ml penicillin, 100 mg/ml streptomycin, 50 mM 2-Mercaptoethanol (all 
from Gibco)   
Biotinylation of cell surface proteins 
Cells surface proteins were biotinylated using Pierce Premium Grade 
Sulfo-NHS-LC-Biotin (Thermo Scientific, PG82075, Zug, Switzerland) 
according to the manufacturer`s instructions. Briefly, 10x10
6
 cells were washed 
with PBS pH 8, then stained with 1 mg/ml of Sulfo-NHS-LC-Biotin and 
incubated for 30 min at room temperature. The dose of Sulfo-NHS-LC-Biotin 
was optimized in preliminary experiments (data not shown). After incubation, 
cells were washed 3 times with PBS pH 8 supplemented with 100 mM glycine. 
Final washing of cells was performed with PBS supplemented with 0.5% bovine 
serum albumin (BSA) (Sigma, A9418-500G, Buchs, Switzerland) and 2 mM 
EDTA (Suppl. Figure 3). 
Validation for biotinylation of cell surface proteins 
Biotinylated and non-biotinylated cells were stained for 5 min on ice, with 
phycoerythrin (PE)- labelled streptavidin at a concentration of 6.25 µg/ml (BD 




non-biotinylated cells were then co-stained with 5 µl (0.25µg) of anti-human 
CD3 BV421 (Biolegend, 300434, London, UK) antibodies and 5µl (0.25µg) and 
7AAD viability dye (BD Pharmingen, 559925, Allschwil, Switzerland) for  
10 min on ice. Flow cytometric analysis was performed with BD FACS ARIA II 
(BD, Allschwil, Switzerland). 
Proliferation analysis of biotinylated cells 
Equal amounts of PBMCs were biotinlyated or left unbiotinylated. All 
cells were then labelled with cell trace violet dye (CTV; Life Technologies, 
C34557, Zug, Switzerland). For this, CTV was diluted in pre-warmed PBS 
(37°C) to a working concentration of 1.25 μM. Cell pellets were resuspended 
with CTV dye solution at a concentration of 1x10
6
 cells/ml and incubated for 20 
min at 37°C on a tube rotator to assure uniform labelling. Following this, five 
times the original staining volume of pre-warmed medium was added and 
incubated for 5 min to remove nonspecific CTV dye in the solution. Next, cells 
were washed and resuspended in cRPMI medium. Biotinylated and non-
biotinylated cells were then cultured for 6 days, stimulated with a mixture of 
anti-CD3, CD2, CD28 mAbs (0.5 ug/ml) or unstimulated. On day 6, cells were 
stained with Fixable Viability Dye eFluor 780 (eBioscience, 65-0865-14, 
Vienna, Austria) and anti-human CD3 BV510 antibody (Biolegend, 300448, 
London, UK). 
Streptavidin labelling of anti-cytokine catch antibodies 
Purified anti-human IL-22 (eBioscience, 12-7229-42, London, UK) and 
anti-human IL-17A (eBioscience, 14-7178-85, London, UK) antibodies were 
labelled with streptavidin using Lightning-Link Streptavidin Conjugation kit 
(Innova Biosciences, 708-0010, Cambridge, UK) according to the 
manufacturer`s instructions. Total amount of 100 µg of both anti-cytokine 
antibodies were used for streptavidin labelling.  




Streptavidin labelled, anti-cytokine catch antibodies were added to 
PBMC`s at a concentration of 10x10
6
 cells in different concentrations, starting 
from 10 µg/ml, 5 µg/ml, 2.5 µg/ml to 1.25 µg/ml and incubated for 20 min on 
ice. Next, goat anti-rat IgG (AF488 conjugated, Invitrogen, A11006, Zug, 
Switzerland) and goat anti-mouse IgG (AF633 conjugated, Invitrogen, 31575, 
Zug, Switzerland) antibodies were used in 20 µg/ml concentration to detect rat 
anti-human IL-22 and mouse anti-human IL-17A streptavidin-labelled catch 
antibodies bound to biotinylated cells surface, respectively. Staining was 
performed on ice for 20 min. Additionally, cells were stained with anti-CD3 
BV421 mAb and 7AAD for 10 min. 
Intracellular cytokine staining 
After resting overnight, CD3+CD4+ T cells were stimulated in 24 well 
plates at a concentration of 2x10
6
/ml in cRPMI medium for 4 hours with 25 
ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, P-8139, Buchs, 
Switzerland) and 1 µg/ml Ionomycin (Sigma-Aldrich, I-0634, Buchs 
Switzerland). Following this, 1 µg/ml of brefeldin A (Sigma-Aldrich, B-7651, 
Buchs, Switzerland) was added for additional 2 hours. After stimulation, cells 
were washed in PBS and stained with fixable viability dye eFluor 780 for 30 
min at 4
o
C (eBioscience, 65-0865-14, Vienna, Austria) followed by staining 
with 5 µl (0.25 µg) of anti-human CD3 (BV421, Biolegend, 300434, London, 
UK) and 5 µl (1 µg) of anti-human CD4 for 15 min at 4
o
C (PE-Cy7, Biolegend, 
400325, London, UK). Before intracellular staining, cells were fixed and 
permeabilized with fixation/permeabilization solution for 20 min at 4
o
C (BD 
Cytofix/Cytoperm Fixation/Permeabilization solution kit, 554714, Allschwil, 
Switzerland). Next, 5 µl (0.25 µg) of anti-human IL-17A AF488 (eBioscience, 
53-7179, Vienna, Austria) and 5 µl (0.06 µg) of anti-human IL-22 PE 




Perm/Wash buffer (BD, 554714, Allschwil, Switzerland) were used for 
intracellular cytokine staining for 30 min at 4
o
C. 
Sorting of IL-17A- and IL-22-secreting CD4+ T cells by a dual 
cytokine secretion assay 
After biotinylation as described above, cells were stained with fixable 
viability dye eFluor 780 for 30 min and anti-human CD3 (BV421, Biolegend, 
300434, London, UK) and anti-human CD4 (PE-Cy7, Biolegend, 400325, 
London, UK) antibodies for 15 min on ice. Next, cells were stained with 
streptavidinylated anti-IL-22 and anti-IL-17A catch antibodies at a concentration 
of 10µg/ml for 20 min on ice. Cells that were not stained with streptavidinylated 
antibodies served as negative controls. For the cytokine secretion, cells were 
stimulated with 25 ng/ml PMA, 1 µg/ml Ionomycin in cRPMI medium at the 
concentration of 1x10
6
 and incubated for 4 hours on the Tube Rotator 
(MACSmix Milteneyi Biotec, 130-090-753, Bergisch Gladbach, Germany). 
After incubation, cells were stained with anti-human IL-17A AF488 and anti-
human IL-22 detection antibodies for 20 min on ice. It will be good to note here 
that the same antibodies were used for intracellular staining as well. Four 
different populations of cells were sorted into PBS based on gates set up with 
“no-catch antibody reagent” controls: 1) IL-17A-producing IL-22-non-
producing Th17 cells, 2) IL-17A-non-producing and IL-22-producing Th22 
cells, 3) both IL-17A- and IL-22-producing Th17/Th22 cells and 4) cells 
producing neither IL-22, nor IL-17A. 
RT-PCR detection of cytokines in sorted cells 
Sorted cells were lysed in RLT Plus RNA lysis buffer (Qiagen, 74034, 
Hombrechtikon, Switzerland). Total RNA was isolated using RNeasy Plus 
Micro kit (Qiagen, 74034, Hombrechtikon, Switzerland). mRNA  was reverse 
transcribed with Revert Aid RT Kit (Thermo Scientific, K1691, Zug, 




PCR was performed on a 7900HT Fast Real-Time PCR system (Thermo 
Scientific, 4329001, Zug, Switzerland) using Maxima Sybr Green/Rox qPCR 
Master Mix (Thermo Scientific, K0223, Zug, Switzerland) protocol with 
primers, IL-22 reverse primer: 5`TAG CAG CGC TCA CTC ATA CTG 3`, 
forward: 5`TTC ATG CTC GCCT AAG GAG GC 3`, IL-17a reverse primer: 
5`CGG ACT GTG ATG TGC AAC CT3`, forward: 5` TCC TCA TTG CGG 









 cells are stated in supplementary 
table 1. Results were normalized to EF1α (eukaryotic translation elongation 
factor 1 alpha) expression for each sample. Gene expression levels, shown in 
arbitrary units, were calculated by subtracting EF1 α cycle threshold (Ct) from 
the gene Ct to get ΔCt value. Arbitrary units for each sample = 10 000 x (2−ΔCt). 
Culture of sorted Th22 and Th17 cells 
Purified Th22 and Th17 cells were expanded in the presence of 1 nM IL-2 as 
a growth factor. After 10 days of expansion, T cells were re-stimulated with a 
combination of anti-CD2, anti-CD3 and anti-CD28 (0.5 ug/ml) monoclonal 
antibodies in cRPMI medium. Supernatants were harvested after 48 h and IL-22 
and IL-17A were measured with human Th17 magnetic bead panel kit 

















Validation of dual cytokine-secretion assay 
The complete cytokine secretion assay consists of streptavidin-labelled anti-
cytokine catch antibodies, which are bound to the biotinylated surface of the 
cells, and fluorescently labelled cytokine detection antibodies (Suppl. Figure 1). 
Biotin labelling of cell surface proteins is the first step of the novel dual 
cytokine-secretion assay. To prove that this step was done correctly, the 
detection of biotinylated cell surface using a PE-labelled streptavidin was 
performed. As demonstrated in Figure 1A, only biotinylated cells were stained 
with streptavidin-PE, as compared to non-biotinylated cells, with approximately 
98 % of viable, CD3+ T cells stained with streptavidin-PE, demonstrating that 
biotinylation of cell surface proteins was successful (Figure 1A, B). The reagent 
(Sulfo-NHS-LC-Biotin) that was used to biotinylate the cells is membrane 
impermeable, water-soluble and biotinylates only primary amines present on the 
surface of the cells. In accordance with that fact, 93.14 ± 1.52 % of biotinylated 
CD3+ T cells were viable, as compared to 96.17 ± 1.52 % of viable non-
biotinylated cells, demonstrating that biotinylation had no effect on cell viability 
(Figure 1C).  
Next, to investigate, if biotinylation activates the cells and induces their 
proliferation, peripheral blood mononuclear cells (PBMC`s) were stimulated 
with an anti-CD2/CD3/CD28 mixture of mAbs and stained with a cell division 
tracking (CTV) reagent. On day 6, 94.0 ± 6.6 % of biotinylated and 92.7 ± 6.3 % 
of non-biotinylated CD3+ T cells proliferated in response to T cell specific 
stimuli. Furthermore, spontaneous proliferation of non-stimulated, biotinylated 




surface biotinylation of T cells influence neither their viability nor their ability 
to proliferate.   
After biotinylation, cells were ready for the next step in the cytokine 
secretion assay procedure: Staining with anti-cytokine catch antibodies. Here, 
we took the advantage of the fact that streptavidin has a very high affinity for 
biotin (Kd ≈ 10-14) [343], and we labelled purified anti-cytokine catch antibodies 
with streptavidin and used them to bind to biotin on the surface of the cells. To 
find the optimal concentration of streptavidin-labelled catch antibodies, which 
cover the whole cell surface, a 10, 5, 2.5, to 1.25 µg/ml titration of both 
antibodies was performed (Figure 2A). To detect these catch antibodies (Ab`s) 
on the surface of the cells, we took the advantage that anti-human IL-22 
antibody (Ab) was of rat origin and anti-human IL-17A Ab was of mouse origin. 
Therefore, we used goat anti-rat IgG AF488 Ab to detect anti-IL-22 catch 
antibody, and goat anti-mouse AF633 Ab to detect anti-IL-17A catch antibody 
on the surface of cells (Suppl. Figure 3). As shown in Figure 2B, concentration-
dependent labelling of the cells was observed, with 1.25 µg/ml and 2.5 µg/ml of 
antibodies not being sufficient to cover the whole surface of cells. Only Ab`s at 
concentration of 5 and 10 µg/ml enabled a complete staining of the cell 
population. As shown on Figure 2B, the percentage of cells labelled with both 
catch antibodies in case of 10 µg/ml concentration reached 97,8 ± 0.75%, we 
decided to use for further assays anti-cytokine catch antibodies at a 
concentration of 10 µg/ml. Dual secretion assay was capable of catching IL-22 
and IL-17A cytokines produced by the cells. Secreted cytokines were bound to 
catch antibodies on the surface of cells and later detected with fluorescently 
labelled detection antibodies.  
IL-22- and IL-17A-secretion assays recognize cytokine-producing 
CD3+CD4+ T cells in similar quantities compared to intracellular 




To analyse intracellular cytokine production, cells were gated on viable 
CD3+CD4+ T cells and IL-22 and IL-17A production was determined  
(Figure 3A). As presented in Figure 3B, the percentage of IL-22
pos
 cells detected 
with secretion assay positively correlated with the percentage of IL-22
pos
 cells 
identified with intracellular staining. More interestingly, similar correlation, was 
found for Th22 cells, which produced IL-22 and didn`t produce IL-17A. In 
addition, positive correlation between secretion assay and intracellular staining 









 cells. We were able to detect cell populations as low as 0.05% 
and 0.06% of IL-22+ and IL-17A+ T helper cells with the dual secretion assay 
(Suppl. Figure 4), suggesting that this secretion assay is as sensitive as 
intracellular cytokine staining. 
Purified Th22 cells are characterized by high expression of IL22, but not 
IL17a mRNA 
In the next step, IL-17A-single positive, double IL-17A/IL-22-producing,  
IL-17A/IL-22-double negative and most importantly, IL-22-single positive cells 
were sorted (Suppl. Figure 4A). During sorting, cells that were not stained with 
anti-cytokine catch antibodies, but were stained with fluorescently labelled 
detection Ab`s, served as controls. Based on these controls, gates were set for 
better estimation of cytokine production by T cells. To avoid cytokine-non-
producing cells non-specifically binding the cytokines produced by neighboring 
cells, the cells were suspended at a concentration of 1x10
6
/ml and incubated on  
a tube rotator to provide constant mixing of cells, thereby avoiding cell-cell 
contact. Although, the production of both cytokines varied between different 
donors, staining with secretion assays allowed sorting of 4 separate populations 




 T cells was significantly higher 




 T cells (p ≤ 0.001) suggesting that there 




 Subsequently, mRNA was isolated from sorted cells and the expression of 
IL22 and IL17A mRNA was quantified by RT-qPCR (Figure 4B). IL-22 
expression was only detected in IL-22-single positive and IL-17A/IL-22-double 
positive cells, but not in IL-17A-single positive and IL-17A/IL-22-double 
negative cells. Similar results were obtained for IL-17A mRNA expression, with 
IL-17A detected only in IL-17A-single positive and IL-17A/IL-22-double 
positive cells. Interestingly, IL22 mRNA was significantly higher expressed in  
IL-22-single positive and double positive cells as compared to double negative 
cells. Moreover, analogous to this finding it was reported for IL17A mRNA 
expression, as IL17A was expressed significantly higher in IL-17A-single 
positive as well as in double positive cells when compared to double negative 
cells.  
In addition, the expression of chemokine receptors, T helper cell-related 














expressed higher mRNA levels of CCR6 and CCR4 chemokines receptors and 




 cells. There was no 
difference in mRNA expression of CCR10, CXCR3, CLA, T-bet, Gata-3, AHR, 





 Th22 cells were purified and expanded in 
culture for 12 days. They were characterized by production of IL-22 and little or 





 Th17 cells, which did not produce IL-22, but produced  
IL-17A (Figure 4C). In conclusion, these results confirm that dual secretion 
assay detects accurately Th22 as well as Th17 cells, and sorted Th22 and Th17 












The first cytokine secretion assay was established in 1995 by Manz and 
colleagues to sort viable cells according to their secreted molecules, secreted to 
a cell-surface affinity matrix [344]. Since then, some commercially available 
secretion assays were developed and consist of anti-cytokine catch reagent (anti-
CD45 Ab linked to an anti-cytokine Ab) and detection Ab binding to a different 
epitope of the cytokine of interest, which is labelled with a fluorescent dye. The 
main restriction of above-mentioned secretion assays is that limited number of 
fluorescently labelled detection antibodies exists and IL-22-secretion assay has 
not been developed yet. 
For a long time, IL-22-producing cells were considered as a subset of Th17 
cells [142]. This was mainly due to the fact that, there are only a few tools 
available to study human Th22 cells, such as intracellular cytokine staining, 
generation of T cell clones and cell sorting based on chemokine receptors [138, 
146, 147]. In the present study, we show that a combination of dual anti-IL-22 
and anti-IL-17A secretion assays, allow to sort viable IL-22-producing Th22 
cells, that do not co-express IL-17A. This novel method expands the 
possibilities to further characterize human Th22 cells, because cells sorted with 
this secretion assay can be sterile handled and characterized, co-cultured with 
other cells or used in humanized mouse models. 
One of the novel and important steps in this currently presented dual-
secretion assay is the biotinylation of cell surface proteins. Our data show that 
biotinylation of cells did not affect cell viability and the ability of cells to 




proliferate spontaneously. Together, these results suggest that, sorted, 
biotinylated cells can be cultured in vitro.  
In the next step, streptavidin labelled anti-cytokine antibodies were used to 
catch cytokines produced by cells. At this step, it was possible to combine more 
than two anti-cytokine catch antibodies, as long as detection antibodies used in 
next step recognize different epitopes of the same cytokine and were labelled 
with different fluorochromes. In the present study, two catch antibodies were 
used, which allowed us to sort Th22 cell that do not express IL-17A and Th17 
cells that do not express IL-22. After culture, the sorted cells kept their profile of 
the initial sorting strategy with Th22 cells producing IL-22 and low amounts of 
IL-17A, and Th17 cells producing IL-17A and not producing IL-22.  
The measurement of transcription factors and chemokines provided further 





T cells expressed higher levels of CCR6 and CCR4 chemokine 




 cells suggesting that previously reported 






 [138, 146], 










 T cells. AhR, has been reported to be essential for IL-22 
expression in Th17 cells [151, 158], γδ T cells [158] and human Th22 cells [138, 
146] in some studies, whereas others have reported that AHR is not absolutely 
required for IL-22 expression [286]. Although it was expressed in relatively high 









cells in the present study.  
To further validate the cytokine profile and quality of purified cells, IL-17A 
and IL-22 production by T cells was compared between intracellular staining 
and the secretion assay. During intracellular staining, permeabilization and 
fixation of cells renders them useless for further functional experiments. In 




is blocked with brefeldin A during intracellular staining. This method gives only 
information about the ability of cells to produce cytokines, without revealing 
their extracellular secretion. In contrast, cell sorting based on their cytokine 
production with a secretion assay gives a capability to culture viable cells and 
study their biology in detail. The cells detected with a secretion assay are the 
cells, which secrete cytokines into the extracellular space resembling more 
closely the in vivo situation. For both presented methods, cells were stimulated 
with PMA and ionomycin, but in case of the secretion assay stimulation took 
place after surface staining, during incubation on tube rotator at 37
o
C, and in 
case of intracellular staining, it took place before surface staining and was 
followed by the addition of brefeldin A. Nevertheless, the percentages of cells 
detected with the secretion assay significantly correlated with percentages of 
cells detected with intracellular staining, suggesting that secretion assay is as 
sensitive in the detection of cytokine-producing cells as intracellular cytokine 
staining. 
In conclusion, for the first time, we were able to sort pure, human Th22 cells 
based on their IL-22 production, which are lacking IL-17A production. Sorted 
cells could be cultured at a later stage and their cytokine profile investigated. 
The combination of two secretion assays, as presented here, gives a possibility 
to sort different subsets of Th22 cells, co-producing other cytokines, such as  
IL-17A and investigate the interaction of these cells with other cells. 
Understanding the differences in the regulation of IL-22 may provide an insight 
into the pathogenic and physiological functions of this cytokine in various 
diseases. This methodology will enable even more than two cytokines to be 
analyzed at the same time. As soon as the pair of antibodies, which detect 
different epitopes of the same cytokine exist, and one of them is labelled with a 
fluorescent dye, multiple anti-cytokine secretion assays may be combined for 
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Figure 1. Validation of cell surface biotinylation. 
Biotinylated and non-biotinylated PBMCs were stained with streptavidin-PE to examine the 
efficiency of biotinylation process (A). In the gate of viable CD3+ T cells, 97.32 ± 4.52% of 
biotinylated CD3+T cells were stained with streptavidin - PE (B). The biotinylation of cells 
does not influence cells viability, as the percentages of viable CD3+T cells were similar 
among biotinylated and non-biotinylated cells (n=3) (C). Next, proliferation of biotinylated 
and non-biotinylated cells in response to anti-CD2, CD3, CD28 mAb stimulation was 
investigated. Similar percentages of biotinylated and non-biotinylated CD3+T cells responded 
to anti-CD2/CD3/CD28 stimulation on day 6 after starting the cultures as measured using the  
cell proliferation dye (CTV). Biotinylation of the cell surface did not induce spontaneous 
proliferation of biotinylated cells (n=4) (D). Two-way Anova test with multiple comparisons 
was applied (**** p<0.0001). 
Figure 2. Titration of anti-cytokine catch antibodies binding to the cell surface. 
Binding of streptavidin-labelled anti-cytokine catch antibodies to biotinylated cell surface was 
analysed, and the titration of the anti-cytokine catch antibodies was performed (A). Rat anti-
human IL-22 and mouse anti-human IL-17A catch antibodies were detected with goat anti-rat  
AF488 and goat anti-mouse AF633 antibodies, respectively (B). Concentration-dependent 
labelling was observed, and optimal dose of 10 µg/ml of both catch antibodies was 
established (n=4). One-way Anova test with multiple comparisons was calculated (*p<0.05, 
** p<0.01) 
Figure 3. Comparison of cytokine production detected by secretion assays and 
intracellular staining. 
The production of IL-17A and IL-22 was analysed using both, the secretion assay and 
intracellular while gating on staining viable, CD3+CD4+T cells (A). The percentage of 

















 Th17 cells (B). 




Figure 4. Sorting and characterization of IL-22-producing Th22 cells and  
IL-17A-producing Th17 cells. 
CD3+CD4+T cells were stained with anti-IL-17A and IL-22 secretion assays and four 









, double negative), expression of IL17A and IL22 was measured with RT-PCR (B). IL22 




 and double positive cells. Whereas, 




 T cells 
(n=5) (B). The percentage of IL-22-positive cells, which do not produce IL-17A varied from 
0.074% to 0.72% of total CD3+CD4+ T cells (A) (n=7) and were significantly higher in 
number as compared to IL-17A/IL-22-double positive cells. No difference in number of 









 cells were cultured in cRPMI medium supplemented with IL-2 for 12 days and 
after the second round of T cells re-stimulation with anti-CD2/CD3/CD28 antibodies, 
production of IL-22 and IL-17A was measured by luminometric bead array. Th22 cells 
produced IL-22 with a very low amount of IL-17A, in contrast Th17 cells produced IL-17A 
with no-co production of IL-22 (C). One-way Anova test for repeated measures was applied 

















































Supplementary figure legends 
Supplementary figure 1. The principle of cytokine secretion assay. 
Biotinylated cells were stained with streptavidin-labeled anti-cytokine catch antibodies. Next, 
cells were kept on the tube rotator in a 37
o
C incubator and secreted cytokines were bound to 
the catch antibodies. In the last step, cytokines bound to the catch antibodies were detected by 
fluorescently labelled anti-cytokines antibodies. 
Supplementary figure 2. Gating strategy for assessment of biotinylated and non-
biotinylated cells proliferation. 
After gating in lymphocytes, doublet cells were excluded and all viable cells were included 
into analysis. CD3+ T cells were separately gated from CD19+ B cells and their proliferation 
was analysed. A representative gating strategy shows cells stimulated with anti-CD2, CD3, 
CD28 mAb`s mixture for 6 days. 
Supplementary figure 3. Validation of cytokine-secretion assay formation - graphical 
explanation. 
Biotinylation of cell surface proteins was detected with fluorescently labelled streptavidin. In 
the next step, anti-cytokine catch antibodies were used to stain the cells. To detect the 
presence of catch antibodies on cell surface, goat anti-rat AF488 antibody and goat anti-
mouse AF633 antibody were used to detect rat anti-human IL-22 Ab and mouse anti-human 
IL-17A Ab, respectively.  
Supplementary figure 4. Detailed staining for representative donors in intracellular 
staining and secretion assays. 
Detailed information about percentage of cells obtained from 2 donors (high and low cytokine 
producers) in secretion assay staining (A) and in intracellular staining (B). Gating strategy 
includes all cells based on forward scatter (FSC) and site scatter (SSC) and excludes dead 
cells using eFluor780 viability dye. Next, CD3+CD4+ T cells were investigated for 








Supplementary figure 5. Protocol for staining IL-22- and IL-17A-producing CD3+CD4+ 
T cells with cytokine secretion assays. 
Detailed protocol of staining, which allows replication of data obtained in the presented paper. 









 sorted T cells.  
mRNA expression of chemokine receptors (CCR10, CCR6, CXCR3, CCR4), skin homing 
marker - CLA, transcription factors (T-bet, Gata-3, RORgt, AHR) and cytokines (IFN-γ, IL-4) 








 sorted T cells. Mann Whitney test was 















































Supplementary table 1. 
 




















Gene  Primer sequence 
CCR10 
forward 5` GAGGCCACAGAGCAGGTTTC 3` 
reverse 5` GGGAGACACTGGGTTGGAAG 3` 
CCR6 
forward 5` GAGAGGGCCCACGTGTATATG 3` 
reverse 5` ATTGATTCCCCGCTCATTGTG 3` 
CXCR3 
forward 5` GAAGTACGGCCCTGGAAGAC 3` 
reverse 5` CGGCGTCATTTAGCACTTGG 3` 
CCR4 
forward 5` AAAGCAAGCTGCTTCTGGTTG 3` 
reverse 5` AGGAAGAGCTCCCCAAATGC 3` 
CLA 
forward 5` GGCTGGGACCTTGTCACTAA 3` 
reverse 5` TCAGCAACAGGAGGAGTTGC 3` 
T-bet 
forward 5` GCAGGGACGGCGGATGTT 3` 
reverse 5` CAAATGAAACTTCCTGGCGCA 3` 
Gata-3 
forward 5` GCGCCGTCTTGATACTTTCAG 3` 
reverse 5` GGGTCACCTGGGTAGCGAAG 3` 
Rorγc 
forward 5` AGCTAGGTGCAGAGCTTCAG 3` 
reverse 5` ATTTGTGTTCTCATGACTGAGCC 3` 
AHR 
forward 5` TGGTTGTGATGCCAAAGGAAG 3` 
reverse 5` AAGCAGGCGTGCATTAGACT 3` 
IL4 
forward 5` ACA GCC TCA CAG AGC AGA AGA CT 3` 
reverse 5` GTG TTC TTG GAG GCA GCA AG 3` 
IFNγ 
forward 5` TCT CGG AAA CGA TGA AAT ATA CAA GTT AT 3` 




6.4 Contributions to publications 
For the publication entitled: “Increased microRNA-323-3p in  
IL-22/IL-17-producing T cells and asthma: a role in the regulation of the TGF-β 
pathway and IL-22 production”, I have contributed to experiments for figure 1 
and figure 2. 
 
For the publication entitled: “Next generation sequencing characterization 
of human IL-22-producing T cells”, I have contributed to all experiments except 
the performance of sequencing and analysis of next generation RNA sequencing 
data. 
 
For the publication entitled: “A novel, dual cytokine-secretion assay for the 
purification of human Th22 cells that do not co-produce IL-17A”, I have 





7 General discussion 
 
T cells are essential cells of the adaptive immune system. Due to their 
highly specific and diverse repertoire of antigen recognizing T cell receptors on 
the surface, T cells can eliminate viral, fungal and bacterial infections. 
Additionally, by releasing cytokines, T cells activate other immune cells, assist 
B cells to produce antibodies and regulate the immune system and tissue cells. 
After antigen recognition during the immune synapse formation and delivery of 
three signals by antigen-presenting cells, CD4+T cells differentiate into effector 
cells that are characterized by subset inducing polarizing cytokines, lineage-
specific transcription factors and a range of cytokines produced to convey 
effector function. The main subsets of effector T helper cells are: Th1, Th2, Th9, 
Th17 and Th22 cells. Among all of these T helper cells subsets, IL-22-producing 
T cells have been characterized to a lesser extent compared to other subsets. In 
this PhD thesis, we have studied human IL-22-producing T cells in depth and 
increased the knowledge about human IL-22-producing T cells.  
MicroRNAs are post-transcriptional gene expression regulators, which 
play a role in the development and effector functions of T cells. For example  
miR-146 and miR-155 enhances Th1-mediated immunity [269, 270]. On the 
contrary, miR-29a and miR-29b are the most potent direct inhibitors of Th1 
differentiation and IFN-γ production [265]. Additionally, polarization of naive T 
cells towards Th17 cells is enhanced mainly by miR155, miR-301 and miR-326 
[278-280, 283]. Nevertheless, miRNA profiling and miRNA functional analysis 
in IL-22-producing T cells have not been addressed so far.  
For the first time, we have analyzed the expression of microRNAs in 
human IL-22-producing T cells and demonstrated that IL-22-producing T cells 
have a distinct miRNA expression pattern. A total of 18 miRNAs were found to 













were significantly up-regulated and miR-874, miR-26a, miR-181a, miR-93, and  





































 cells was increased in comparison to the cells, which did not 
produce these cytokines. 
Pathway analysis of miRNAs differentially expressed in IL-22-positive  
T cells suggested that these miRNAs might impact the development, 
proliferation and immune responses of T cells. miR-886-5p and miR886-3p 
were excluded from the above mentioned pathway analysis as the corresponding 
PCR probes were recently shown to recognize a 139 nt long noncoding RNA 
nc886 that functions as a repressor of interferon-induced, double-stranded RNA-
activated protein kinase [302]. Integrated pathway and target analysis suggested 
that miR-323-3p could target and modulate the expression of the genes 
regulating cellular responses to TGF-β, which is known to play a crucial role in 
Th17 cells differentiation and regulation of IL-22 production by Th17 cells 
[145].  
SMAD3, SMAD5 and CDKN1B were determined as direct miR-323-3p 
targets with SMAD3 and CDKN1B being inhibited by the transfection of  
miR-323-3p mimics into T cells. As it is known that SMAD3 and SMAD5 are 
able to translocate to the nucleus, where together with transcriptional activators 
and repressors they modulate gene expression [305] and CDKN1B controls the 
cell cycle progression at G1 [306], we propose that miR-323-3p might impact 
the progression of the cell cycle and the expression of cytokines. Interestingly, 
strong down-regulation of IL-22 mRNA level as well as its protein level was 
observed, when T cells were transfected with miR-323-3p.  
Although miR-323-3p targets several genes from the TGF-β pathway, 
which is an important cytokine needed for Th17 cell differentiation which 




cooperates with TGF-β in the suppression of IL-22 production. One of the 
possible explanations of this finding is that miR-323-3p may regulate TGF-β-
related genes other than the ones investigated in this study. Nevertheless, this 
data, for the first time shows that miRNA-323-3p acts as a negative regulator of 
IL-22 production by T cells.  
IL-22 may be produced by Th22 and Th17 cells, therefore IL-22-
producing T cells consist of a mixture of IL-22-single and IL-22/IL-17 co-
producing T cells. In our study, we show that the expression of miR-323-3p is 
higher in IL-22/IL-17-double positive T cells and IL-17-single positive T cells 
as compared to IL-22-single positive T cells. This observation may suggest that 
higher levels of miR-323-3p inhibit IL-22 production and thus shift IL-22/IL-17 
co-producing T cells towards the Th17 phenotype that lack IL-22 production. As 
IL-22 is known as bi-functional cytokine that acts differently on epithelial cells 
depending on the cytokine milieu [345], miR-323-3p may play a role as a 
potential regulator of IL-22 production that may influence the final effect of 
Th17/Th22 cells on tissues.  
Recently published studies suggest that both Th17 and Th22 cells play an 
important role in allergic diseases [290, 291, 346]. For example, Th17 cells have 
been demonstrated to play a central role in neutrophilic airway inflammation 
[290, 291]. Additionally, in mouse models, IL-22 has been shown to suppress 
recruitment of eosinophils and goblet cell hyperplasia in antigen-induced airway 
inflammation [194]. Moreover, in the serum of patients with asthma, levels of 
both IL-22 and IL-17 have been shown to be increased [190, 313]. In agreement 
with this data, increased expression of miR-323-3p in PBMC`s from patients 
with asthma was observed when compared to control, healthy individuals, 
suggesting that altered expression of miR-323-3p may potentially impact 
immune responses in allergic diseases. However, further studies about the role 





In conclusion of first part, we show the increased expression of  
miR-323-3p in IL-22/IL-17-producing T cells and in PBMCs from patients with 
asthma compared to healthy controls. In addition, we demonstrate that  
miR-323-3p targets multiple genes from the TGF-β signaling pathway and 
inhibits IL-22 production by T cells. These results suggest that miR-323-3p 
might impact T cell responses in asthma. 
 
Considering the fact that IL-22 plays a unique role in the regulation of 
epithelial cells, next we characterized human IL-22-producing T cells from 
palatine tonsils, where T cells are in the close proximity to epithelial cells. 
Viable human IL-22-producing T cells were isolated from palatine tonsil 
mononuclear cells (TMCs) with the use of an in-house generated IL-22-
secretion assay followed by next generation sequencing of IL-22-positive and 
IL-22-negative T cells. 
In the first steps, to better characterize IL-22-producing T cells from 
tonsils, we used intracellular cytokine staining for Th1/Th2/Th17/Th22/Treg 
cytokines (IL-17, IL-10, IL-4, IL-13, IFN-γ, IL-22). Interestingly, co-expression 
analysis of IL-17, IL-10, IL-4, IL-13 and IFN-γ by IL-22-producing CD4+ T 
cells revealed that most of IL-22-producing cells either co-express IL-4 only or 
co-express IL-17 only or produce IL-22 alone. Furthermore, when similar 
analysis was performed for IL-17-producing, IL-4-producing, IFN-γ-producing 
and IL-10-producing T cells, percentage of IL-17-single positive, IL-10-single 
positive, IL-4-single positive or IFN-γ-single positive cells was statistically 
higher when compared to IL-22-single producing T cells. Since the effect of  
IL-22 on epithelial cells may depend on other cytokines, in this situation IL-4 
and IL-17, this results support the common understanding that IL-22 is a 
bifunctional cytokine, which may play both a protective and pro-inflammatory 




Later, we established that TLR3 ligand (Poly (I:C)), IL-7 and IL-23 
stimulation of TMCs induced high IL-22 production on mRNA as well as on 
protein level. After analyzing other TLR ligands and cytokines, this is the first 
report of this set of stimuli being able to induce IL-22 production. It is possible 
that TLR3 ligand, Poly (I:C), via activation of STAT3 signaling induces IL-22 
[347]. At the same time, IL-7 serves as a survival factor [348] and IL-23 induces 
direct IL-22 production [349]. However, the mechanisms of IL-22 induction by 
the stimuli of TLR3 ligand, IL-7 and IL-23 remain to be explained thoroughly.  
Because of the fact that anti-IL-22 secretion assay is not commercially 
available, we generated it in our laboratory. Anti-CD45 antibody was conjugated 
with anti-IL-22 antibody to form an anti-IL-22 catch reagent that was used in the 
first step of IL-22 secretion assay. During the validation of catch reagent 
formation, we show that all white blood cells have been stained with anti-IL-22 
catch reagent. Next, before performing next generation RNA sequencing 
analysis, we proved that cells sorted according to IL-22 production express high 
levels of IL-22 mRNA and during long term culture keep the profile of IL-22-
producing cells. So far, most of the attempts to characterize IL-22-producing T 
cells were based on intracellular cytokine staining, generation of Th22 cell 
clones or sorting the IL-22-positive cells according to expression of chemokine 
receptors [147, 287, 288]. The method, which we present here in this thesis is 
novel and for the first time allows to sort viable, human IL-22-producing T cells.  
Next generation RNA sequencing analysis of IL-22-producing and IL-22-
non-producing T cells revealed 57820 genes differentially expressed in IL-22-
positive cells compared to IL-22-negative cells. List of 601 genes that fulfilled 
the criteria of: genes expressed in at least 3 out of 4 donors in either IL-22-
positive or IL-22-negative T cells with the intensity values above 0, with a log2 
value ratio ≥ 1 or ≤ -1 and differently expressed with the p Value below 0.01 has 
been included in the analysis with the MetaCore-Data-mining and pathway 




13 genes as coding transcription factors and 6 genes as chemokine receptors (G 
protein-coupled receptors) have been identified within the list as differentially 
expressed between IL-22-positive and IL-22-negative T cells.  
Among the cytokines listed, IL-22-producing T cells express higher levels 
of IL-22, IL-17A, IL-17F, IL-1A, IL-9, IL-21, IL-26 and CCL1, CCL2, CCL20.  
As IL-17A and IL-17F production by IL-22-positive T cells have been described 
previously [141], other molecules are reported for the first time to be  
co-expressed together with IL-22. This data suggests that IL-22-producing T 
cells via IL-22 production may influence cells by the production of other 
cytokines and chemokines and exhibit a broader effect of the immune system. 
As IL-22 is known to be bi-functional, depending on the cytokine milieu [324], 
it remains unclear what would be the effect of IL-22 on the immune cells in the 
context of the above mentioned co-produced cytokines. At the same time, IL-22-
producing T cells differentially express CCR5, CXCR4 and CXCR6 that may be 
used as surface markers for IL-22-producing cells identification. Interestingly, 
CCR5 is described as inflammatory chemokine receptor [323]. CCR5 is 
expressed by Th1 cells. However more is known about the expression of CCR5 
on Treg cells, where it is critical for the migration to tissues infected with fungal 
pathogens [325] and Leishmania major [326]. Additionally, during graft-versus-
host disease, CCR5 mediates accumulation of Tregs in graft-versus-host disease 
targeted organs [327]. In the islet allograft transplant model, Treg cell migration 
from blood to inflamed transplant tissue requires CCR5 expression [328]. 
Similar role in related to migration of cells to tissues was found for CXCR6, 
which promote NKT cells residence in peripheral tissues like liver and lung [329]. 
In contrast, another chemokine receptor expressed by IL-22-positive T cells - 
CXCR4, mediate CCR7-independent entry to lymph nodes [330]. It is 
interesting that chemokine receptors expressed differentially on IL-22-positive 
cells may guide the migration of IL-22-postive cells to inflamed tissue, where by 




Finally, Th22 cells-related transcription factor was not described 
previously and we show for the first time among the potential transcription 
factors upregulated in IL-22-producing T cells - PPARG and among 
transcription factor downregulated in IL-22-producing T cells - FOS, bind 
directly to IL22 promotor and may influence the IL-22-production directly 
[SABiosciences` proprietary database]. Role of other transcription factors 
upregulated (MAF, EPAS1, MSC, CITED) and downregulated (EGR1, EGR4, 
ZXDA) in IL-22-positive T cells has to be investigated further. 
In summary, present study for the first time shows the next generation 
sequencing analysis of human IL-22-producing T cells and proposes the genes 
that characterize human IL-22-producing T cells. Further investigation of 
biological function of those molecules in IL-22 secreting T cells is required. 
Additionally, there is certainly a need to distinguish between IL-22-producing 
Th17 cells and IL-22-producing Th22 cells and better characterize pure human 
Th22 cells.  
 
The main cytokine of Th22 cells, IL-22, can be also produced by Th17 
cells and therefore there is still an ongoing debate and no clear distinction 
between Th17 and Th22 cells in humans. Most of the confusion in the assigning 
IL-22 as Th17 rather than Th22 cytokine comes from a discrepancy between 
mouse and human data. Among the mouse T helper subsets, Th17 cells are the 
major source of IL-22 and IL-22 is named as a Th17 cytokine [141-143]. In 
contrast, IL-22 production by human cells does not correlate with either RORγt 
or IL-17A expression [139] and only 10-18% of IL-22-producing T cells in 
blood co-express IL-17A [287]. To improve the current methodology that 
enables better characterization of human IL-22-producing T cells, we developed 
a novel, dual cytokine secretion assay to purify human Th22 cells that do not co-
produce IL-17A. So far, the commercially available secretion assays consists of 




fluorescently labelled detection Ab that binds to a different epitope of the 
cytokine of interest. One of the main restrictions of those secretion assays is 
limited number of fluorescently labelled detection antibodies that exist and the 
fact that the IL-22-secretion assay has not been developed so far. On the 
contrary, our newly developed cytokine secretion assay consists of anti-IL-22 
and anti-IL-17A catch antibodies, which via a biotin-streptavidin interaction are 
bound to the biotinylated surface of the target cell and anti-IL-22 and IL-17A 
detection antibodies labelled with a fluorescent dye, which detects cytokines 
bound to these catch antibodies.  
The secretion assay presented in this thesis is an improved version of 
secretion assay used for the next generation sequencing analysis of human tonsil 
T cells. As we faced technical problems to combine two secretion assay that 
would detect IL-22 and IL-17 simultaneously, we decided to change the main 
principle of the methodology and instead of using catch reagent consisting of 
anti-CD45 conjugated to anti-cytokine catch reagent, we used streptavidin-
labelled anti-cytokine antibody that binds to the biotinylated cell surface. 
Importantly, the biotinylation of cell surface proteins that takes place in 
the currently used dual-secretion assay did not affect the viability and ability of 
cells to proliferate and did not activate the cells. These results suggest that 
biotinylated and sorted cells can be further cultured in vitro. In the subsequent 
step, anti-cytokine antibodies labelled with streptavidin were used to detect and 
bind cytokines produced by cells. This step opens new possibilities, since any 
purified anti-cytokine antibody can be labelled with streptavidin and used as 
anti-cytokine catch antibody as long as fluorescently labelled detection 
antibodies used in next step recognize different epitopes of the same cytokine. 
Obviously, with multiple-anti-cytokine secretion assay`s combined, this 
methodology enables one to analyze more than two cytokines at the same time. 
Especially, this method may be useful for hard do detect cytokines, for which 




The validation of dual-secretion assay required comparison with 
intracellular staining of cytokines in terms of percentage of cells detected with 
both methods. In the present study, the percentages of cells detected with 
intracellular staining significantly correlated with the percentages of cells 
detected with the dual-secretion assay, suggesting that secretion-assay 
developed by us is as sensitive as intracellular cytokine staining for the detection 
of cytokine-producing cells.  
Finally, cells sorted with dual-secretion assay, namely Th17 cells that 
produce IL-17A and do not co-express IL-22 and Th22 cells that produce IL-22 
and do not co-express IL-17A, were characterized in terms of transcription 
factors and chemokines receptors expression. Higher levels of mRNA 









 cells, suggesting that the previously reported 
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 T cells. Although, aryl hydrocarbon receptor (AhR) was expressed in 









cells in the present study. 
Therefore this might imply what has been reported previously that AhR is not 
required for IL-22 expression in T cells [145].  
In summary, this novel method expands the possibilities to further 
characterize human Th22 cells that may be co-cultured with other cells or used 
in humanized mouse models. Additionally, the method may be used to identify 












Conclusion and outlook 
We conclude here that the data demonstrated in these studies is novel in 
terms of three aspects. First of all, for the first time miRNA expression profile 
analysis in human IL-22-producing T cells has been performed and a new 
miRNA-323-3p has been reported as a potential negative regulator of IL-22 
production from T cells. Secondly, next generation sequencing of human IL-22-
producing T cells sorted with our in-house generated novel IL-22 secretion 
assay was performed and a full profile of IL-22-producing cells including 
potential transcription factors was demonstrated. Finally, a novel, double 
cytokine secretion assay that allows sorting of viable Th22 cells that do not co-
produce IL-17A was generated.  
The novel methods developed here will enable better understanding and 
characterization of human Th22 cells may provide novel therapeutic options in 
the treatment of diseases like psoriasis, atopic dermatitis, rheumatoid arthritis, 
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